Yoon Hang Kim MD Complex Regional Pain Syndrome (CRPS) remains one of the most challenging chronic pain conditions we encounter. Patients typically present with severe, disproportionate pain following injury or surgery, often accompanied by sensory disturbances, temperature and color changes, swelling, and motor dysfunction. The underlying pathophysiology involves both peripheral and central sensitization, with sympathetic nervous system dysregulation and neuroinflammation playing key roles. Management requires a multidisciplinary approach combining medications, physical rehabilitation, psychological support, and sometimes interventional procedures. Two modalities that deserve attention for refractory cases are radiofrequency ablation (RFA) and low-dose naltrexone (LDN) — each targeting different aspects of the condition's complex pathophysiology. Radiofrequency Ablation RFA uses radiofrequency energy delivered through a needle electrode to disrupt nerve conduction. For CRPS, the typical targets are sympathetic ganglia: the stellate ganglion for upper extremity involvement, or the lumbar sympathetic chain for lower extremity cases. Continuous RFA produces thermal neurolysis, while pulsed RFA (PRF) offers neuromodulation without significant tissue destruction. The evidence base includes case reports, retrospective series, and limited comparative studies showing prolonged pain reduction — sometimes lasting months to years — particularly in patients with sympathetically maintained pain. Systematic reviews suggest moderate evidence, though larger randomized trials are still needed. Potential complications  include temporary pain flare, numbness, paresthesia, bruising, and infection. Stellate ganglion procedures carry risk of Horner syndrome. Rare but serious complications include vascular injury, pneumothorax, and paradoxically, worsening or new-onset CRPS. Pulsed RFA generally carries lower risk than continuous thermal ablation. Low-Dose Naltrexone LDN — typically dosed at 1–4.5 mg daily — represents an off-label use of the opioid antagonist naltrexone. At these low doses, the mechanism shifts from opioid receptor blockade to modulation of Toll-like receptor 4 (TLR4) on glial cells. This attenuates microglial activation and reduces the neuroinflammatory cascade that drives central sensitization. The CRPS-specific evidence comes primarily from case reports and retrospective analyses. The landmark 2013 report by Chopra and Cooper documented remission of prominent CRPS symptoms — including dystonic spasms, fixed dystonia, allodynia, and vasomotor changes — in patients who had failed conventional therapies. More recent retrospective data suggests higher response rates in patients with neuropathic pain profiles, including CRPS. That said, high-quality randomized controlled trials specifically in CRPS remain lacking, and broader chronic pain reviews show variable results. Side effects  are generally mild and often transient: vivid dreams, drowsiness, dizziness, nausea, headache, and insomnia. These frequently resolve with continued use or dose adjustment. Serious adverse events are rare, and tolerability is high. Comparing the Two Approaches No head-to-head trials compare RFA and LDN in CRPS, so we're left extrapolating from their different mechanisms and available evidence. RFA  targets sympathetically mediated pain directly. For the right patient — one with a positive diagnostic sympathetic block — it can provide substantial, relatively rapid relief. However, it's invasive, requires specialized expertise, and carries procedural risks. LDN  works systemically, addressing the glial-driven neuroinflammation and central sensitization that underlie many CRPS cases. It's non-invasive, well-tolerated, and inexpensive, but benefits typically develop gradually over weeks to months. From a safety standpoint, LDN has clear advantages: oral administration, minimal adverse effects, and very low discontinuation rates. RFA, while generally safe when performed under imaging guidance, involves inherent procedural risks. Practical Considerations Both interventions are typically reserved for patients who haven't responded adequately to first-line measures. Diagnostic sympathetic blocks help identify RFA candidates, while LDN often requires a trial of several weeks to months before efficacy can be assessed. Patient selection should consider the predominant pain mechanism. Those with clear sympathetically maintained features may be better candidates for RFA, while patients with more central or inflammatory components may respond well to LDN. In practice, these aren't mutually exclusive — some patients benefit from both approaches as part of a comprehensive treatment plan. Larger randomized trials are needed to clarify optimal protocols, comparative effectiveness, and how to best identify responders to each modality. References Chopra P, Cooper MS. Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013;8(3):470-476. McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V. Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series. J Pain Res. 2023;16:1993-1998. Rupp A, et al. Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023;24(11):1270-1281. Vuka I, et al. Interventional radiofrequency treatment for the sympathetic nervous system: a review article. Pain Ther. 2021;10(1):19-34. Yang J, et al. The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: a systematic review. J Pain Res. 2023;16:1017-1023.

A Clinical Perspective from Two Decades of LDN Practice Yoon Hang Kim, MD, MPH, FAAMA Direct Integrative Care & Functional Medicine via Telemedicine Serving IA, IL, MO, GA, FL, TX www.directintegrativecare.com Introduction Long COVID, formally known as post-acute sequelae of SARS-CoV-2 infection (PASC), continues to challenge healthcare systems globally. Millions of patients experience persistent symptoms including fatigue, cognitive impairment, pain, and sleep disturbances that can persist for months or years after initial infection. As a physician who has prescribed low-dose naltrexone (LDN) for over two decades and presented at multiple LDN Research Trust conferences, I have witnessed firsthand how this therapy can benefit patients with complex chronic conditions. The emerging evidence for LDN in Long COVID represents a natural extension of its established applications in fibromyalgia, chronic fatigue syndrome, and autoimmune disorders. This article synthesizes current evidence, mechanisms, and clinical applications of LDN for Long COVID, drawing from both published research and clinical experience. While LDN remains an off-label intervention, the growing body of preliminary evidence warrants serious consideration by clinicians seeking options for their patients with post-COVID symptoms. Understanding Low-Dose Naltrexone Naltrexone is an opioid antagonist conventionally administered at doses exceeding 50 mg for managing opioid and alcohol dependence. However, at low doses (typically 0.5–4.5 mg), LDN operates through fundamentally different pathways. Rather than serving as a direct opioid blocker, LDN functions primarily as an anti-inflammatory agent and immune modulator (Younger et al., 2014). This mechanistic shift is crucial to understanding LDN’s therapeutic potential. At low doses, naltrexone acts as a TLR4 antagonist, mitigating microglial activation and reducing neuroinflammation. Additionally, transient opioid receptor blockade triggers a rebound increase in endogenous endorphin production, which modulates immune function (Toljan & Vrooman, 2018). These mechanisms make LDN particularly relevant for conditions characterized by neuroinflammation and immune dysregulation—hallmarks of Long COVID. LDN Functional Medicine Perspective Long Covid - Current Research Status Observational Studies and Pilot Data Multiple observational studies have reported improvements in fatigue, pain, sleep, cognition, and daily functioning after one to three months of LDN therapy, with response rates of 50–60%. A landmark study from Dublin tracked 38 Long COVID patients and documented gains in energy levels, pain reduction, concentration, sleep quality, and overall recovery perception after two months of treatment (O’Kelly et al., 2022). A 2022 pilot study involving 36 patients with post-COVID fatigue demonstrated enhanced fatigue scores and quality of life when LDN (4.5 mg/day) was combined with transdermal NAD⁺ (Campagnolo et al., 2024). While this study lacked a control group, the magnitude of improvement was notable. A 2025 systematic review reinforced these findings, suggesting LDN improves fatigue, cognition, sleep, pain, and functioning, with 73.9% of patients reporting positive responses. A November 2025 meta-analysis further demonstrated statistically significant reductions in fatigue, brain fog, and headaches (Darkoh et al., 2025). Patient-Reported Outcomes A landmark 2025 study published in Proceedings of the National Academy of Sciences  analyzed patient-reported outcomes from over 3,900 individuals with ME/CFS and Long COVID (Eckey et al., 2025). LDN achieved a net approval score of 49.4%, with patients reporting improvements in fatigue (41.5%), post-exertional malaise (33.2%), and brain fog (42.3%). Notably, LDN was among the most effective treatments with one of the lowest instances of side effects. Ongoing Clinical Trials Several randomized controlled trials are advancing to clarify LDN’s efficacy. The British Columbia trial (NCT05430152), a double-blind, placebo-controlled study assessing LDN’s impact on fatigue and inflammatory markers in post-COVID fatigue syndrome, has completed enrollment (Naik et al., 2024). The NIH RECOVER-TLC pediatric/young adult LDN trial targets fatigue reduction in ages 6–25. The LIFT trial (NCT06366724) at Brigham and Women’s Hospital combines LDN with pyridostigmine for ME/CFS and Long COVID with orthostatic intolerance. Proposed Mechanisms of Action LDN’s potential in Long COVID stems from several hypothesized mechanisms: Glial Modulation and Neuroinflammation Reduction: LDN acts as a TLR4 antagonist, mitigating microglial activation in the brain. This mechanism may address the persistent neuroinflammation contributing to fatigue, pain, and cognitive dysfunction in Long COVID (Younger et al., 2014). Restoration of Ion Channel Function: Groundbreaking 2025 research from Griffith University demonstrated that LDN (3–4.5 mg/day) restores TRPM3 ion channel function in natural killer cells from Long COVID patients. This finding addresses immune dysregulation—a proposed biomarker in Long COVID—and correlates with quality-of-life improvements (Sasso et al., 2025). Endorphin Upregulation: Transient opioid receptor blockade boosts endogenous endorphin production, modulating immune function and pain perception—mechanisms paralleling those observed in ME/CFS and fibromyalgia. Clinical Approach: Lessons from Two Decades of Practice Drawing from my experience prescribing LDN across conditions including fibromyalgia, autoimmune disorders, and chronic pain, I have observed that approximately one-third of patients do not respond to standard LDN protocols. This clinical reality has shaped my approach to Long COVID. Assessing Endorphin Reserve Before initiating LDN, I assess each patient’s endorphin reserve by evaluating functional capacity. Key questions include: How long have they been symptomatic? Do they achieve restorative sleep? What is their baseline energy? How quickly do they recover from setbacks? Patients with severely depleted reserves require different dosing strategies than those with moderate illness. Dosing Strategies Standard protocols typically initiate oral LDN at 0.5–1.5 mg nightly, titrating to 3–4.5 mg/day over weeks, with treatment durations of 2–6+ months. However, for severely ill patients or those with low functional capacity, I recommend starting at microgram doses (ultra-low-dose naltrexone) and titrating very slowly—sometimes over months rather than weeks. The LDN Research Trust recognizes three dosing categories: ultra-low dose (microgram dosing), very-low dose (0.1–0.5 mg daily), and low dose (1–4.5 mg, sometimes up to 10 mg). Safety Profile LDN demonstrates a favorable safety profile with low discontinuation rates across chronic conditions. Common initial side effects include vivid dreams, insomnia, nausea, dizziness, fatigue, and mood alterations—typically resolving with dose adjustments. In the Dublin study, only 5.3% of patients discontinued due to adverse effects (O’Kelly et al., 2022). Important contraindications include concurrent opioid use, and LDN lacks formal guideline endorsement for Long COVID pending additional RCT data. Clinical Summary Common Dose: 0.5–4.5 mg daily (titrated slowly over weeks) Primary Mechanisms: TLR4 antagonism, glial modulation, TRPM3 restoration, endorphin upregulation Symptoms Targeted: Fatigue, brain fog, chronic pain, sleep disturbances, post-exertional malaise Key Evidence: Multiple pilot studies positive; RCTs in progress (NCT05430152, NCT06366724) Regulatory Status: Off-label; not FDA-approved specifically for Long COVID Limitations of Current Evidence Despite promising signals, current evidence is constrained by small sample sizes (typically <100 participants), lack of randomization in observational studies, and potential biases including spontaneous recovery. Phenotypic heterogeneity in Long COVID, variable infection-to-treatment intervals, and concurrent therapies limit generalizability. Systematic reviews appropriately classify LDN as “promising but low-certainty,” emphasizing the need for well-designed RCTs. Conclusion LDN represents a low-risk, accessible option for managing Long COVID symptoms, supported by growing preliminary evidence and compelling mechanistic insights. As randomized controlled trials mature in 2026, clearer efficacy data will emerge. In the meantime, clinicians should weigh individual patient profiles, assess endorphin reserve, titrate doses appropriately, and monitor for side effects. For patients struggling with persistent post-COVID symptoms and limited treatment options, LDN merits consideration as part of a comprehensive management strategy. As the quote often attributed to W. Edwards Deming reminds us: “A bad system will beat a good person every time.” For Long COVID patients navigating a healthcare system with limited approved treatments, LDN offers hope—not as a panacea, but as one promising tool in an evolving therapeutic landscape. Low-Dose Naltrexone: An Emerging Treatment for Long COVID References Campagnolo, N., Johnston, S., Collatz, A., Staines, D., & Marshall-Gradisnik, S. (2024). Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain, Behavior, & Immunity – Health, 36 , 100733. https://doi.org/10.1016/j.bbih.2024.100733 Darkoh, A., Ngwa, A. D. K., Akinbile, A. G., Ogunleye, A. E., & Osondu, C. (2025). Does low-dose oral naltrexone alleviate symptoms of Long COVID? A systematic review and meta-analysis. COVID, 5 (12), 198. https://doi.org/10.3390/covid5120198 Eckey, M., Li, P., Morrison, B., Bergquist, J., Davis, R. W., & Xiao, W. (2025). Patient-reported treatment outcomes in ME/CFS and long COVID. Proceedings of the National Academy of Sciences, 122 (28), e2426874122. https://doi.org/10.1073/pnas.2426874122 Naik, H., Cooke, E., Boulter, T., Dyer, R., Bone, J. N., Tsai, M., Cristobal, J., McKay, R. J., Song, X., & Nacul, L. (2024). Low-dose naltrexone for post-COVID fatigue syndrome: A study protocol for a double-blind, randomised trial in British Columbia. BMJ Open, 14 (5), e085272. https://doi.org/10.1136/bmjopen-2024-085272 O’Kelly, B., Vidal, L., McHugh, T., Woo, J., Avramovic, G., & Lambert, J. S. (2022). Safety and efficacy of low dose naltrexone in a long covid cohort: An interventional pre-post study. Brain, Behavior, & Immunity – Health, 24 , 100485. https://doi.org/10.1016/j.bbih.2022.100485 Sasso, E. M., Eaton-Fitch, N., Smith, P., Muraki, K., & Marshall-Gradisnik, S. (2025). Low-dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients. Frontiers in Molecular Biosciences, 12 , 1582967. https://doi.org/10.3389/fmolb.2025.1582967 Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences, 6 (4), 82. https://doi.org/10.3390/medsci6040082 Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, 2018 , bcr2017221405. https://doi.org/10.1136/bcr-2017-221405 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 About the Author Yoon Hang Kim, MD, MPH, FAAMA is a board-certified preventive medicine physician with an integrative medicine fellowship from the University of Arizona. He has been prescribing LDN for over two decades and has presented at multiple LDN Research Trust conferences internationally. Dr. Kim established integrative oncology programs at Miami Cancer Institute and the University of Kansas Medical Center. He currently practices functional medicine via telemedicine through Direct Integrative Care ( www.directintegrativecare.com ), serving patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. He is the author of Low Dose Naltrexone Therapy: An Evidence-Based Review and Case Histories  and the LDN Primer clinical guide. Disclosure: The author reports no conflicts of interest. LDN is an off-label treatment and patients should consult with qualified healthcare providers before initiating therapy.

By Yoon Hang "John" Kim, MD, MPH About the Author:  Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Dr. Kim is a recognized expert in low-dose naltrexone (LDN) therapy, having authored three books and more than 20 articles on the subject. He founded and moderates the LDN Support Group with over 7,000 members and has presented at multiple LDN Research Trust conferences. His clinical practice, Direct Integrative Care, serves patients across multiple states with a focus on autoimmune conditions, chronic pain, and complex chronic illness. Low-Dose Naltrexone in the Management of Sjögren's Syndrome -LDN Sjogren Sjögren's syndrome is one of those conditions that can quietly steal quality of life. It's a systemic autoimmune disease that primarily attacks moisture-producing glands, leaving patients with chronically dry eyes and mouth—but often so much more. Fatigue, joint pain, brain fog, and involvement of various organ systems can make daily life a real struggle. Low-dose naltrexone (LDN) has emerged as a promising option for these patients. At doses typically ranging from 0.5 to 4.5 mg per day, LDN behaves very differently from standard-dose naltrexone (50–100 mg) used in addiction medicine. Instead of blocking opioid receptors around the clock, LDN creates a brief, transient blockade that actually upregulates  the body's endorphin system and modulates immune function. While the published evidence remains limited to case reports, what we're seeing clinically is encouraging. Understanding Sjögren's Syndrome Sjögren's syndrome is a chronic autoimmune disorder where the immune system mistakenly attacks the lacrimal (tear) and salivary glands. The hallmark symptoms—dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia)—are what most people think of, but that's often just the tip of the iceberg. Many patients experience what I call "non-classic" or systemic Sjögren's: debilitating fatigue, widespread joint and muscle pain, peripheral neuropathies, cognitive difficulties, and involvement of the lungs, kidneys, skin, or nervous system. Some patients have minimal sicca symptoms but profound systemic manifestations. This heterogeneity is important to recognize because treatment approaches may differ. The disease predominantly affects women (approximately 9:1 ratio compared to men) and typically presents between ages 40 and 60, though it can occur at any age. Diagnosis involves clinical evaluation, serological tests (anti-SSA/Ro and anti-SSB/La antibodies), and sometimes minor salivary gland biopsy. Standard treatments focus on symptom management—artificial tears, saliva substitutes, and immunosuppressive agents like hydroxychloroquine—but no cure exists, and many patients remain symptomatic despite conventional therapy. How Does Low-Dose Naltrexone Work? LDN's mechanism is fascinating and counterintuitive. By briefly blocking opioid receptors (typically for just a few hours when taken at bedtime), LDN triggers a compensatory upregulation of endogenous endorphin production and enhances receptor sensitivity. This creates a "rebound" effect that persists throughout the day. Perhaps more importantly for autoimmune conditions, LDN antagonizes Toll-like receptor 4 (TLR4) on microglia and macrophages. This reduces pro-inflammatory cytokine release and calms neuroinflammation—a mechanism that may explain why patients often report improvements in fatigue, pain, and brain fog. The safety profile is remarkably favorable. The most common side effects are vivid dreams or mild sleep disturbance, which typically resolve within the first few weeks or can be managed by adjusting the timing of the dose. LDN must be obtained from compounding pharmacies since it's not commercially available in low-dose formulations. What Does the Published Evidence Show? The published evidence for LDN in Sjögren's syndrome consists primarily of case reports, but the results are consistent and encouraging. Dr. Scott Zashin, a rheumatologist at UT Southwestern, published the initial case report in 2019 describing a 47-year-old woman with suspected Sjögren's who had failed standard therapy. After initiating LDN, she experienced significant clinical improvement with reduction of inflammatory markers. In a 2020 follow-up publication, Zashin reported two additional cases. A 66-year-old woman with documented Sjögren's who had discontinued hydroxychloroquine due to concerns about retinal toxicity experienced recurrence of joint pain and elevated inflammatory markers. After starting LDN at 1 mg and titrating to 2 mg daily, her pain resolved and her ESR and CRP normalized. A 24-year-old woman with documented Sjögren's presenting with chronic widespread pain, fatigue, headaches, and markedly elevated inflammatory markers (ESR 90 mm/h, CRP 14.2 mg/L) showed progressive improvement after LDN titration, ultimately achieving normal inflammatory markers at one-year follow-up on 8.5 mg daily. A 2023 review in the Mediterranean Journal of Rheumatology  by de Carvalho and Skare examined LDN across rheumatological conditions and concluded that while data is limited, LDN appears to be a promising and safe option for pain management in Sjögren's syndrome. Notably, the published cases consistently show improvement in systemic symptoms—pain, fatigue, and inflammatory markers—rather than the sicca symptoms themselves. This makes sense given LDN's immunomodulatory mechanisms. Comparing Treatment Approaches Feature Standard Treatment LDN ± Ketosis Primary Goal Manage dryness; suppress immune activity Modulate immune response; reduce inflammation; support metabolic health Best For Sicca symptoms; preventing organ damage Fatigue, chronic pain, brain fog, neuropathy Availability Standard pharmacies; often insurance-covered Compounded LDN (not typically covered); ketosis via dietary modification Evidence Level High (established standard of care) Low to moderate (case reports, clinical experience) LDN should be viewed as an adjunct therapy, not a replacement for appropriate rheumatological care. Patients with Sjögren's syndrome benefit from a team approach—rheumatology, ophthalmology, dentistry, and, when appropriate, integrative medicine. My Clinical Experience: LDN + Ketosis In my own practice, I've had the opportunity to work with numerous Sjögren's patients—both those with classic presentations (predominant dry eyes and dry mouth) and those with non-classic, systemic manifestations (fatigue, widespread pain, neuropathy, brain fog). What I've observed has been genuinely exciting. Patients who combine LDN with nutritional ketosis have shown excellent responses. The rationale for this combination makes physiological sense: ketosis itself has well-documented anti-inflammatory and neuroprotective effects, and ketones serve as an alternative fuel source that may support mitochondrial function in the setting of chronic inflammation. When paired with LDN's immunomodulatory properties, the synergy appears meaningful. I've seen patients experience significant reductions in fatigue and pain, clearing of brain fog, and improvements in overall quality of life. Some patients with classic sicca symptoms have even reported modest improvements in dryness, though as the literature suggests, systemic symptoms tend to respond more robustly than glandular dysfunction. This combination—LDN plus therapeutic ketosis—represents the kind of integrative approach I find most valuable: addressing the underlying inflammatory and metabolic terrain rather than simply suppressing symptoms. It's low-risk, well-tolerated, and puts patients in an active role in their own healing. Of course, my clinical observations aren't controlled trials, and individual responses vary. But when conventional options have been exhausted or are poorly tolerated, this approach offers real hope. The Bottom Line Sjögren's syndrome remains challenging to treat, particularly for patients whose primary complaints are fatigue, pain, and cognitive difficulties rather than (or in addition to) dryness. Low-dose naltrexone offers a mechanistically plausible, low-risk option that has shown consistent benefits in published case reports and in clinical practice. For patients interested in optimizing their response, combining LDN with nutritional ketosis represents a promising integrative strategy. While we await larger controlled trials, the favorable safety profile and clinical observations to date make this an approach worth considering—ideally in partnership with healthcare providers who understand both the potential and the limitations of this therapy. Low-Dose Naltrexone LDN in the Management of Sjögren's Syndrome At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Carsons, S. E., & Blum, M. A. (2025). Sjogren syndrome. In StatPearls . StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK431049/ Cleveland Clinic. (n.d.). Sjogren's syndrome . https://my.clevelandclinic.org/health/diseases/4929-sjogrens-syndrome de Carvalho, J. F., & Skare, T. (2023). Low-dose naltrexone in rheumatological diseases. Mediterranean Journal of Rheumatology, 34 (1), 1–6. https://doi.org/10.31138/mjr.34.1.1 LDN Research Trust. (n.d.-a). How low dose naltrexone works . https://ldnresearchtrust.org/how-low-dose-naltrexone-works LDN Research Trust. (n.d.-b). Low dose naltrexone (LDN) and Sjogren's syndrome . https://ldnresearchtrust.org/low-dose-naltrexone-ldn-and-sjogren%E2%80%99s-syndrome-dr-pamela-smith Mayo Clinic. (n.d.). Sjogren's syndrome: Symptoms and causes . https://www.mayoclinic.org/diseases-conditions/sjogrens-syndrome/symptoms-causes/syc-20353216 National Health Service. (n.d.). Sjögren's syndrome . https://www.nhs.uk/conditions/sjogrens-syndrome/ Sjogren's Foundation. (n.d.). Understanding Sjogren's . https://sjogrens.org/understanding-sjogrens The American College of Rheumatology. (n.d.). Sjogren's disease . https://rheumatology.org/patients/sjogrens-disease Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences, 6 (4), 82. https://doi.org/10.3390/medsci6040082 Zashin, S. (2019). Sjogren's syndrome: Clinical benefits of low-dose naltrexone therapy. Cureus, 11 (3), e4225. https://doi.org/10.7759/cureus.4225 Zashin, S. (2020). Sjogren's syndrome and clinical benefits of low-dose naltrexone therapy: Additional case reports. Cureus, 12 (7), e8948. https://doi.org/10.7759/cureus.8948

Yoon Hang "John" Kim, MD, MPH About the Author Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN (Low-Dose Naltrexone) for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles on LDN and integrative medicine, and has helped establish integrative medicine programs at institutions nationwide. Professional: www.yoonhangkim.com   |  Clinical: www.directintegrativecare.com A Personal Note Before diving into the clinical details, I want to share something personal. A close family member of mine was completely incapacitated by mold-related illness. The fatigue was crushing, the brain fog impenetrable, and the road to diagnosis frustratingly long. Watching someone you love struggle with a condition that many physicians don’t recognize—or worse, dismiss—is heartbreaking. But here’s the good news: they made a full recovery. It wasn’t quick, it wasn’t easy, and it required a systematic approach that addressed every layer of the illness. That experience deepened my commitment to understanding mold-related conditions and helping others navigate this challenging journey. If you or someone you love is struggling, please know that recovery is possible. Healing from Mold Illness: A Comprehensive Approach Integrating Low-Dose Naltrexone Introduction Mold-related illness—often called Chronic Inflammatory Response Syndrome (CIRS)—is one of the most misunderstood conditions in modern medicine. It arises from exposure to biotoxins in water-damaged buildings and triggers a cascade of immune dysregulation that can affect virtually every system in the body. Patients often present with an overwhelming constellation of symptoms: crushing fatigue, cognitive impairment (the dreaded "brain fog"), chronic pain, and a profound sense that something is deeply wrong—even when standard labs come back "normal." What many people don’t realize is that up to 25% of the population carries genetic susceptibility to CIRS (Dooley et al., 2024). That’s a staggering number. A recent systematic review confirmed that the Shoemaker Protocol remains the only treatment with documented clinical efficacy for CIRS—and it works better than protocols designed for similar conditions like ME/CFS (Dooley et al., 2024). In my practice, I’ve found that while foundational interventions—removing exposure, binding toxins, treating colonization—form the backbone of treatment, adjunctive therapies like low-dose naltrexone (LDN) can make a meaningful difference. LDN doesn’t cure mold illness, but for many patients, it helps calm the immune storm enough to make the deeper healing work more tolerable and effective. This article walks through a comprehensive approach to mold-related illness, combining validated protocols with promising supportive therapies. Step 1: Find the Mold and Get Away from It I cannot overstate this: you cannot heal in a toxic environment . It’s like trying to put out a fire while someone keeps pouring gasoline on it. Dr. Bruce Hoffman puts it bluntly: "For many people, this is the most critical, yet most difficult step. Without removing exposure, treatment cannot succeed" (Hoffman, n.d.). I know this step can feel impossible. Sometimes it means leaving your home, your job, or making financial sacrifices that seem unreasonable. But I’ve seen patients spin their wheels for years—taking every supplement, trying every protocol—only to finally improve when they addressed the exposure. The body simply cannot outpace ongoing toxic exposure. Testing Your Environment The ERMI (Environmental Relative Moldiness Index) test provides a quantitative PCR analysis of 36 mold species. Dr. Shoemaker’s research suggests a safe score is ≤2 for most patients, and below -1 for those with highly elevated C4a levels (Shoemaker, 2010). After remediation, the HERTSMI-2 test can verify whether the building is safe to re-enter—scores below 11 are generally the target. Getting It Done Right Professional remediation should follow EPA and IICRC guidelines. This isn’t a DIY project—improper remediation can actually make things worse by stirring up spores. Key priorities include fixing water intrusion, removing damaged materials, controlling humidity, and using HEPA filtration. And here’s something patients often underestimate: re-exposure can happen within 15 minutes of entering a contaminated building. Stay out until it’s truly safe. Step 2: Bind and Eliminate the Toxins Here’s the frustrating biology: in genetically susceptible people, about 95% of bile—which carries biotoxins—gets reabsorbed in the gut and recirculated. It’s like a merry-go-round of toxins that never stops. Binders interrupt this cycle by grabbing onto the toxins in your gut and escorting them out through your stool. The Gold Standard: Cholestyramine Cholestyramine (CSM) remains the most effective binder we have, backed by two double-blind, placebo-controlled studies. It works because its positive charge attracts negatively charged biotoxins. The standard protocol calls for four doses daily on an empty stomach—which, I’ll admit, can be challenging to maintain. Many patients start with Welchol, which is easier to tolerate even if it’s only about 25% as effective (Shoemaker, 2010). Other Options For patients who can’t tolerate prescription binders, we sometimes turn to activated charcoal, bentonite clay, chlorella, or zeolite. These don’t have the same evidence base, but Dr. Neil Nathan has observed that different mycotoxins may bind preferentially to different agents—for instance, bentonite and charcoal seem to work well for trichothecenes (Nathan, n.d.). Some clinicians have also found success with okra and beet extracts, though peer-reviewed data is still pending. Step 3: Clear the Colonizers Most CIRS patients harbor something called MARCoNS—Multiple Antibiotic Resistant Coagulase Negative Staphylococci—deep in their nasal passages. These bacteria form protective biofilms and release toxins that break down MSH (melanocyte-stimulating hormone), a key anti-inflammatory peptide. It’s a vicious cycle: low MSH allows MARCoNS to thrive, and MARCoNS further suppress MSH (Shoemaker, 2010). Testing A deep nasal swab sent to a specialized lab like MicrobiologyDX can identify MARCoNS. About 80% of CIRS patients test positive, with roughly 60% showing methicillin resistance. The culture also reveals which antibiotics the bacteria are resistant to—critical information for treatment planning. Treatment BEG nasal spray—a compounded formula containing Bactroban, EDTA, and Gentamicin—is the primary treatment. The EDTA dissolves the biofilm, allowing the antibiotics to reach the bacteria. The standard protocol is two sprays in each nostril, three times daily, for at least a month. Some stubborn cases require up to six months of treatment. A word of caution: when MARCoNS die, they release endotoxins that can temporarily worsen symptoms. I recommend patients be on an effective binder for at least a month before starting nasal treatment. Alternatives for those who can’t tolerate BEG include colloidal silver rinses, EDTA-only formulations, or Xlear (xylitol-based spray). Some practitioners are even exploring probiotic nasal sprays to reestablish healthy flora. Don’t Forget the Fungus Fungal colonization of the sinuses is often overlooked but can produce mycotoxins locally. Treatment may include amphotericin B nasal spray, oral antifungals like itraconazole, and biofilm disruptors. Interestingly, addressing sinus mold often resolves MARCoNS simultaneously—the bacterial and fungal biofilms seem to support each other. Step 4: Support Your Body’s Detox Pathways Binders are essential, but they’re only part of the equation. The body has its own detoxification machinery—liver, kidneys, lymphatics, skin—and that machinery needs support, especially when it’s been overwhelmed by chronic toxin exposure. Glutathione: The Master Antioxidant Glutathione depletion is nearly universal in patients with mycotoxin exposure (Guilford & Hope, 2014). This matters because glutathione is central to phase II liver detoxification and protects cells from oxidative damage. Supplementation options include liposomal glutathione (oral), N-acetylcysteine/NAC (a precursor), IV glutathione for more severe cases, and intranasal glutathione for sinus and neurological support. A survey found that over 62% of patients using intranasal glutathione reported meaningful benefits (Hope, 2013). Additional Support Methylation support (methylfolate, methylcobalamin, SAMe) helps keep detox pathways running smoothly. Infrared sauna therapy promotes toxin elimination through sweat—preliminary research shows reduced mycotoxin levels when combined with other therapies (Rea et al., 2009). Phosphatidylcholine supports cell membranes and liver function. And don’t underestimate the basics: vitamin D, magnesium, zinc, CoQ10, and B vitamins are commonly depleted in CIRS patients and should be repleted. Step 5: Calm the Allergic Fire Many mold patients develop what we call Mast Cell Activation Syndrome (MCAS)—their mast cells become hypersensitive and release histamine and other inflammatory chemicals at the slightest provocation. This can make treatment incredibly difficult because patients react to everything: foods, supplements, even medications meant to help them. Strategies That Help H1 and H2 antihistamines can block histamine effects. Mast cell stabilizers like ketotifen and cromolyn sodium prevent degranulation. Natural options include quercetin and other bioflavonoids. A low-histamine diet reduces triggers. DAO (diamine oxidase) supplementation helps those with impaired histamine breakdown. Perhaps most importantly, patients need to identify and avoid their personal triggers—which can include certain foods, fragrances, temperature extremes, and stress. The Cell Danger Response Some researchers believe that mold toxicity triggers a "Cell Danger Response"—a protective shift where cells prioritize defense over energy production. This may explain why so many CIRS patients feel stuck in a "freeze" state, unable to muster the energy for normal activities. Supporting mitochondrial function with nutrients like CoQ10, ribose, and carnitine may help cells transition out of this defensive mode. Where Low-Dose Naltrexone Fits In Now we get to LDN—and I want to be clear about what it is and isn’t. LDN is not  a cure for mold illness. It doesn’t kill mold, it doesn’t bind mycotoxins, and it won’t work if you skip the foundational steps. But for many patients, it’s a valuable tool that helps calm the immune chaos and makes everything else work better. How It Works At standard doses (50 mg), naltrexone blocks opioid receptors and is used for addiction treatment. At low doses (typically 1.5–4.5 mg), it does something quite different: it briefly blocks opioid receptors, triggering a rebound increase in endorphins and enkephalins—the body’s natural feel-good and immune-regulating chemicals. LDN also inhibits Toll-like receptor 4 (TLR4) on microglial cells in the brain, reducing the neuroinflammation that causes so much of the cognitive dysfunction in mold illness. It shifts cytokine balance away from pro-inflammatory (IL-6, TNF-α, TGF-β1) and toward regulatory (IL-10). For patients with MCAS, this shift can be game-changing—the LDN Research Trust reports that about 60% of MCAS patients experienced improvement in symptoms like brain fog, fatigue, and GI distress after starting LDN. When to Introduce It Timing matters. I typically introduce LDN after  patients have addressed environmental exposure, started binder therapy, and achieved at least partial reduction in their inflammatory burden. Starting too early—when the immune system is still in full-blown crisis mode—can sometimes backfire and intensify symptoms. Clinical observation suggests that patients with the HLA type 4-3-53 may respond particularly well to LDN. Patient surveys indicate that most who tried LDN for CIRS rated it "critically important or very helpful" in their recovery (Richmond Functional Medicine, 2024). And unlike NSAIDs—which carry risks of GI bleeding, kidney damage, and cardiovascular problems—LDN’s side effects are minimal and usually temporary. Dosing: Low and Slow For mold patients, especially those with chemical sensitivity, I start very low—0.25 to 0.5 mg—and titrate up gradually over weeks. The goal is usually 1.5–4.5 mg, taken at bedtime to align with natural endorphin production. Some patients experience vivid dreams or insomnia initially; if this persists, switching to morning dosing often helps. Important caveats: LDN is contraindicated if you’re taking opioid medications (it can trigger withdrawal), and caution is warranted in liver impairment. You’ll need a compounding pharmacy—standard naltrexone comes in 50 mg tablets, far too high for LDN use. Other Functional Medicine Approaches Worth Considering Heal the Gut Mycotoxins wreak havoc on the gut microbiome, reducing beneficial species like Lactobacillus reuteri and decreasing overall diversity. Research shows that a healthy gut microbiota can actually help eliminate mycotoxins naturally (Draper et al., 2021). Specific probiotics (Lactobacillus rhamnosus, Bifidobacterium bifidum), prebiotics, and an anti-inflammatory diet that avoids commonly contaminated foods (coffee, nuts, dried fruit, rice) all support gut recovery. Follow the Biomarkers The Shoemaker Protocol includes sequential correction of specific inflammatory markers: ADH/osmolality (desmopressin), MMP-9 (omega-3s and no-amylose diet), VEGF, C3a (statins), C4a, TGF-β1 (losartan or VIP), and MSH. The final step—VIP nasal spray—can only begin after MARCoNS is cleared. It’s methodical, but there’s a reason: each step builds on the last. Emerging Options Mild hyperbaric oxygen therapy (mHBOT) has shown promise in case reports, with one recent case documenting complete symptom resolution after 40 sessions (Frontiers in Immunology, 2025). Ozone therapy, peptide protocols, and other integrative approaches continue to be explored. These aren’t first-line treatments, but for refractory cases, they may offer additional tools. Healing from Mold Illness: A Comprehensive Approach Integrating Low-Dose Naltrexone Final Thoughts Recovering from mold illness is a marathon, not a sprint. It requires patience, persistence, and a systematic approach that addresses every layer of the problem: the environment, the toxins, the colonizers, the depleted detox pathways, and the overactive immune system. LDN isn’t a magic bullet, but for many patients, it’s a valuable piece of the puzzle. Its ability to calm neuroinflammation, stabilize mast cells, and reduce the persistent fatigue of CIRS makes it a rational addition to the toolkit—as long as it’s integrated with, not substituted for, the foundational treatments. I think of it this way: the Shoemaker Protocol is the road map, and LDN is one of the vehicles that can make the journey more bearable. We still need better research—randomized controlled trials specifically in CIRS populations—but the clinical experience and mechanistic rationale are compelling enough that I regularly incorporate LDN into my treatment plans. If you’re struggling with mold illness, know that recovery is possible. I’ve seen it in my patients, and I’ve seen it in my own family. It takes time, it takes the right approach, and it takes a willingness to address the root causes—but the other side of this illness is absolutely reachable. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN (Low-Dose Naltrexone) for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles on LDN and integrative medicine, and has helped establish integrative medicine programs at institutions nationwide. Direct Integrative Care At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality. Yoon Hang Kim, MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Dooley, M., Vukelic, A., & Jim, L. (2024). Chronic inflammatory response syndrome: A review of the evidence of clinical efficacy of treatment. Annals of Medicine and Surgery, 86 (12), 7248–7254. https://doi.org/10.1097/MS9.0000000000002718 Guilford, F. T., & Hope, J. (2014). Deficient glutathione in the pathophysiology of mycotoxin-related illness. Toxins, 6 (2), 608–623. https://doi.org/10.3390/toxins6020608 Hoffman, B. (n.d.). 12 Steps of the Shoemaker Protocol. Hoffman Centre for Integrative Medicine. https://www.drbrucehoffman.com/post/shoemaker-protocol Holtorf, K. (2022). Mold illness and CIRS. In L. Elsegood (Ed.), The LDN Book 3: Low dose naltrexone—The latest research on viral infections, long COVID, mold toxicity, longevity, cancer, depression and more . LDN Research Trust. Hope, J. (2013). A review of the mechanism of injury and treatment approaches for illness resulting from exposure to water-damaged buildings, mold, and mycotoxins. The Scientific World Journal, 2013 , 767482. https://doi.org/10.1155/2013/767482 LDN Research Trust. (n.d.). Mold toxicity: Can low dose naltrexone help? https://ldnresearchtrust.org/mold-toxicity-can-low-dose-naltrexone-ldn-help Patten, D. K., Schultz, B. G., & Berlau, D. J. (2018). The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy, 38 (3), 382–389. https://doi.org/10.1002/phar.2086 Rea, W. J., Pan, Y., & Griffiths, B. (2009). The treatment of patients with mycotoxin-induced disease. Toxicology and Industrial Health, 25 (9–10), 711–714. https://doi.org/10.1177/0748233709348281 Shoemaker, R. C. (2010). Surviving mold: Life in the era of dangerous buildings . Otter Bay Books. Shoemaker, R. C., House, D., & Ryan, J. C. (2013). Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health, 5 (3), 396–401. https://doi.org/10.4236/health.2013.53053 Surviving Mold. (n.d.). The 12-step Shoemaker Protocol overview. https://www.survivingmold.com/legal-resources/12-step-protocol-overview Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 Disclaimer: This article is for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare provider familiar with biotoxin illness. Individual responses to treatment vary, and protocols should be tailored to each patient’s specific presentation and tolerances.

Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com In integrative medicine and functional medicine, women experiencing perimenopause and menopause often seek natural menopause supplements to address hormonal imbalances that conventional approaches may not fully resolve. Among the botanical and nutritional options available, Diindolylmethane (DIM) and Vitex agnus-castus (chasteberry) stand out as particularly useful tools—DIM for supporting healthy estrogen metabolism, and chasteberry for optimizing pituitary signaling. This review explores their biochemical mechanisms, clinical evidence, safety profiles, and practical applications. Because accurate diagnosis matters, I'll also discuss how these supplements fit within personalized treatment plans. If you're new to integrative medicine, expect your first appointment to involve thorough assessment and collaborative goal-setting—these supplements work best as part of a broader therapeutic relationship, not as standalone fixes. The Clinical Challenge of Menopausal Hormone Dysregulation Before diving into specific supplements, it helps to understand why so many women seek alternatives to conventional hormone replacement therapy. The menopausal transition involves far more than simple estrogen decline—it represents a fundamental reorganization of the hypothalamic-pituitary-ovarian axis that unfolds over years, often with unpredictable symptom patterns. During perimenopause, the clinical picture is frequently one of relative estrogen dominance rather than deficiency. Irregular ovulation leads to inadequate progesterone production, while estrogen levels may actually surge erratically before their eventual decline. This creates symptoms like breast tenderness, bloating, mood instability, heavy bleeding, and sleep disruption—symptoms that don't always respond well to estrogen-based therapies. Integrative and functional medicine approaches recognize that optimizing how the body processes and eliminates estrogen may be as important as addressing absolute hormone levels. This is where DIM and chasteberry offer their greatest clinical utility. Understanding DIM in Integrative Medicine for Menopause DIM is derived from cruciferous vegetables—broccoli, cauliflower, Brussels sprouts, cabbage. When we eat these vegetables, a precursor compound called indole-3-carbinol (I3C) converts in the stomach to form DIM, the bioactive metabolite responsible for most clinical effects. Beyond menopause, DIM is being explored for other conditions related to estrogen metabolism. The Biochemistry of Estrogen Metabolism To appreciate how DIM works, we need to understand estrogen metabolism. Estrogens—primarily estradiol (E2), estrone (E1), and estriol (E3)—undergo Phase 1 liver metabolism via cytochrome P450 enzymes, producing hydroxylated metabolites through three primary pathways: 2-hydroxyestrone (2-OHE1)  is generally considered the most favorable metabolite, with weak estrogenic activity and potential antiestrogenic effects in breast tissue. 4-hydroxyestrone (4-OHE1)  is more concerning—it's associated with oxidative DNA damage and potentially genotoxic quinone formation. 16α-hydroxyestrone (16α-OHE1)  has strong estrogenic activity and may promote cellular proliferation in estrogen-sensitive tissues. The ratio of 2-OHE1 to 16α-OHE1 has attracted significant research attention as a potential biomarker for estrogen-related disease risk, though clinical correlations remain an active area of investigation. Mechanisms of DIM as a Functional Medicine Tool DIM modulates Phase 1 liver detoxification by influencing the cytochrome P450 enzyme CYP1A1. Its preferential induction of this enzyme favors the 2-hydroxyestrone pathway over the 16α-hydroxyestrone route. This metabolic shift can reduce estrogenic signaling in peripheral tissues, making DIM valuable for addressing estrogen dominance symptoms. It's worth noting that DIM supports hormonal balance for chronic symptom management—it's not intended for acute conditions or as a quick fix. Beyond Phase 1 metabolism, DIM may support Phase 2 conjugation pathways and promote healthier estrogen receptor signaling. Some research suggests DIM acts as a selective estrogen receptor modulator (SERM), potentially blocking more potent estrogens from receptor binding while exerting mild estrogenic effects of its own. This nuanced mechanism may explain its clinical utility across varying hormonal states. DIM also demonstrates anti-inflammatory properties through NF-κB signaling modulation and may support cellular health through effects on cell cycle regulation and apoptotic pathways—effects that extend its potential applications beyond simple hormone balancing. Clinical Evidence for DIM in Menopause Management Research supports DIM's capacity to alter estrogen metabolism meaningfully. Studies in postmenopausal women, including those on hormone therapy, show significant improvements in urinary estrogen profiles. Supplementation typically produces measurable increases in the 2-OHE1/16α-OHE1 ratio within weeks, suggesting relatively rapid metabolic effects. One study also demonstrated DIM's anti-inflammatory properties and positive impact on PMS symptoms, further supporting its therapeutic potential. A particularly relevant consideration: DIM's interaction with exogenous hormone therapy. By enhancing estrogen clearance, DIM may reduce the biological activity of administered hormones. This can be therapeutically useful when estrogen-dominant symptoms persist despite standard HRT protocols, but patients on hormone therapy may need dose adjustments when adding DIM. While large-scale trials specifically examining DIM for menopausal symptom relief remain limited, clinical experience and mechanistic data support its use for symptoms associated with estrogen excess or impaired estrogen metabolism. Breast tenderness, cyclical bloating, fibrocystic breast changes, and heavy perimenopausal bleeding often respond favorably, particularly when these symptoms suggest relative estrogen dominance. Practical Considerations for DIM Supplementation Bioavailability matters with DIM supplements. The compound is lipophilic and poorly absorbed in its native form. Enhanced-bioavailability formulations using microencapsulation or phospholipid complexes may offer superior absorption, though comparative clinical data remains limited. Standard dosing typically ranges from 100-300 mg daily of enhanced-bioavailability DIM. Optimal doses vary based on body weight, symptom severity, and concurrent hormone use. Starting low and titrating based on response is reasonable. Common side effects are generally mild: temporary darkening of urine (with a characteristic odor reflecting metabolite excretion), mild GI upset, or headache during initial use. These typically resolve with continued use or dose adjustment. DIM is generally considered safe for short-term use, but long-term safety hasn't been well established. Chasteberry's Role in Functional Medicine for Hormonal Symptoms Chasteberry (Vitex agnus-castus) is one of the most extensively studied botanical medicines for female hormonal complaints. Native to the Mediterranean, it's been used medicinally for over two thousand years—historical applications ranged from promoting lactation to suppressing libido (hence "chasteberry"). During the Middle Ages, monks used it to lower sexual desire. Today it's commonly used as an herbal supplement in integrative medicine, and modern research has refined our understanding of its mechanisms. How Chasteberry Works in Integrative Approaches Chasteberry's primary mechanism involves dopaminergic activity through binding to dopamine D2 receptors in the anterior pituitary. This suppresses prolactin secretion from lactotroph cells—an effect with significant downstream hormonal consequences. Prolactin, while essential for lactation, inhibits the hypothalamic-pituitary-gonadal axis when chronically elevated. Even modest prolactin elevations within the "normal" lab range can impair progesterone production and contribute to luteal phase deficiency. By normalizing prolactin levels, chasteberry indirectly supports LH pulsatility and enhances corpus luteum function, improving progesterone output. This makes chasteberry particularly valuable for premenstrual and perimenopausal presentations characterized by relative progesterone deficiency. Unlike bioidentical progesterone supplementation, which directly replaces the hormone, chasteberry works upstream to support the body's own progesterone production—a distinction that appeals to patients seeking more physiologic interventions. Beyond dopaminergic effects, chasteberry extracts contain compounds that interact with opioid receptors (particularly mu and kappa subtypes) and may bind to estrogen receptor beta. These additional mechanisms likely contribute to effects on mood, pain perception, and vasomotor symptoms, though the clinical significance of each pathway remains under investigation. Evidence-Based Benefits of Chasteberry for Menopause The clinical evidence for chasteberry in menopause continues to grow. Randomized controlled trials demonstrate significant reductions in vasomotor symptoms compared to placebo, with effect sizes approaching low-dose hormone therapy in some studies. Chasteberry has also been shown to help alleviate other menopausal symptoms, making it a promising option. Research using the Greene Climacteric Scale—a validated instrument measuring menopausal symptoms across vasomotor, psychological, and somatic domains—shows significant improvements in total scores and subscales with chasteberry supplementation. Anxiety reduction appears particularly robust, consistent with its dopaminergic and opioidergic activities. Meta-analyses examining chasteberry for PMS confirm strong efficacy, with improvements across physical and psychological symptom domains. Given the overlapping symptoms between severe PMS and perimenopause, these findings support chasteberry's utility during the menopausal transition. Emerging research also suggests potential benefits for sleep quality, mood stability, and cognitive symptoms during menopause, though these applications need further controlled investigation. Dosing and Formulation Considerations Chasteberry supplements vary considerably in preparation methods, standardization, and dosages. Traditional preparations used dried berries, while modern standardized extracts concentrate specific marker compounds. Standard doses include 20-40 mg daily of concentrated extract (often standardized to agnuside or casticin content). The German Commission E recommends 30-40 mg daily of dried fruit extract. Clinical response typically requires sustained use over several menstrual cycles, with most studies showing significant effects after three months. This delayed onset reflects the time needed for hormonal recalibration—something to communicate to patients so they have realistic expectations. Combining DIM and Chasteberry: Synergy in Functional Medicine In practice, combining DIM and chasteberry targets complementary pathways—peripheral estrogen detoxification and central hormonal signaling—for enhanced relief in estrogen-dominant conditions. Theoretical and Practical Synergies The mechanistic rationale is compelling. DIM addresses estrogen metabolism at the hepatic level, promoting conversion to less proliferative metabolites and enhancing clearance. Simultaneously, chasteberry optimizes pituitary signaling, supports progesterone production, and reduces inhibitory effects of elevated prolactin. For the perimenopausal woman with erratic estrogen levels and inadequate progesterone opposition, this combination addresses both sides of the hormonal equation. The typical presentation suitable for this combination includes heavy or irregular periods, breast tenderness, bloating, mood instability, and sleep disruption—symptoms suggesting both estrogen excess and progesterone deficiency. While no RCTs have evaluated DIM and chasteberry together, mechanistic rationale combined with clinical experience supports this pairing. Practitioners report benefits for mood stabilization, reduced hot flash frequency and severity, more regular cycles during perimenopause, and improvement in estrogen-dominant symptoms. The combination may be particularly valuable when single-agent therapy provides incomplete relief, or when assessment reveals dysfunction in both estrogen metabolism and progesterone production. Clinical Implementation Strategies Several practical considerations guide clinical decision-making: Sequential vs. Simultaneous Initiation : Some practitioners prefer introducing one agent at a time to assess individual response; others initiate both simultaneously when the clinical picture strongly supports combination therapy. Either approach works depending on circumstances. Monitoring Parameters : Symptom diaries, menstrual patterns, and periodic hormone testing (including estrogen metabolite ratios when available) help optimize dosing. The 2-OHE1/16α-OHE1 ratio provides objective data on DIM's metabolic effects. Duration of Therapy : Both agents typically require sustained use. Three-month trial periods with systematic reassessment allow adequate time for hormonal recalibration. Transition Strategies : As patients progress through menopause, their hormonal needs evolve. The combination that addresses perimenopausal estrogen dominance may need modification when absolute estrogen deficiency predominates later. Patients should talk with their healthcare provider before starting or combining these supplements to ensure safety and appropriate monitoring. Safety Considerations in Integrative and Functional Medicine Both DIM and chasteberry have favorable safety profiles at standard doses, though several considerations warrant attention. DIM Safety Profile DIM is generally well-tolerated at 100-300 mg daily of enhanced-bioavailability preparations. Common effects include darkened urine, mild GI symptoms, and occasional headache—typically transient and dose-related. More significant considerations: Drug Interactions : DIM's induction of cytochrome P450 enzymes could theoretically affect metabolism of medications cleared through these pathways. Clinically significant interactions appear uncommon, but awareness is warranted for medications with narrow therapeutic windows. Hormone Therapy Interactions : DIM may enhance estrogen clearance, potentially reducing HRT efficacy. Monitor for symptom recurrence that might indicate need for hormone dose adjustment. Hormone-Sensitive Conditions : Patients with hormone-sensitive cancers should use DIM only under oncologic supervision. Theoretical benefits of favorable estrogen metabolism must be weighed against the complexity of these conditions. Chasteberry Safety Profile Chasteberry demonstrates excellent tolerability in clinical trials, with adverse event rates similar to placebo. Side effects are typically mild: GI upset, headache, skin reactions. Important considerations: Dopaminergic Medications : Given chasteberry's D2 receptor activity, theoretical interactions exist with dopaminergic medications including certain antipsychotics, antiemetics, and Parkinson's disease treatments. Clinical significance is uncertain, but concurrent use warrants monitoring. Hormone-Sensitive Conditions : Patients with hormone-sensitive cancers should use chasteberry only under appropriate supervision. Pregnancy : Discontinue if pregnancy occurs—effects on early pregnancy aren't fully characterized. Fertility Treatments : Women undergoing assisted reproductive technologies should generally avoid chasteberry, as its pituitary effects could interfere with treatment protocols. Laboratory Assessment in Functional Medicine Practice Specialized testing can guide and monitor botanical hormone support. Urinary Estrogen Metabolites Comprehensive urinary hormone panels measuring estrogen metabolites provide objective data on metabolism pathways. The 2-OHE1/16α-OHE1 ratio serves as a primary marker. These tests also assess 4-hydroxyestrone levels and methylation status of catechol estrogens, providing a complete picture. Serial testing before and after DIM initiation can document metabolic improvements and guide dose optimization. Serum Hormone Panels Standard assessments including estradiol, progesterone, FSH, LH, and prolactin help characterize the hormonal landscape. Prolactin measurement is particularly relevant when considering chasteberry—elevated baseline levels predict stronger response. Timing relative to menstrual cycle significantly affects interpretation and should be standardized. DUTCH Testing The Dried Urine Test for Comprehensive Hormones (DUTCH) combines assessment of sex hormones, their metabolites, adrenal hormones, and organic acids in a single panel—useful for protocol design and monitoring. Menopause and Chronic Disease Prevention Menopause isn't just about managing hot flashes—it's a pivotal moment for long-term health. The North American Menopause Society and American College of Obstetricians and Gynecologists recognize that this transition significantly elevates risks for cardiovascular disease, osteoporosis, and metabolic dysfunction including type 2 diabetes. Functional medicine practitioners view menopause as an opportunity for proactive health optimization, not just symptom suppression. Through comprehensive testing and individualized risk assessment, we can guide women toward interventions that demonstrably improve long-term outcomes. Botanical therapeutics like chasteberry have shown clinical efficacy for reducing menopausal symptoms and supporting hormonal balance. When integrated thoughtfully, they can help alleviate breast tenderness, mood swings, and vasomotor symptoms while improving quality of life. Complementary approaches also deserve mention. Research from institutions like the University of Arizona's Andrew Weil Center for Integrative Medicine supports practices like tai chi and acupuncture for reducing hot flash frequency and severity. These address physical symptoms while also supporting psychological well-being and stress resilience. The National Center for Complementary and Integrative Health (NCCIH), part of the NIH, provides helpful resources for both practitioners and patients seeking safe, effective integrative strategies. Using these resources, women can make informed decisions about supplements, lifestyle modifications, and complementary therapies that fit their individual situations. The functional medicine model emphasizes prevention and patient empowerment throughout menopause. Through personalized nutrition, targeted supplementation, and evidence-based complementary approaches, women can meaningfully reduce chronic disease risk while effectively managing symptoms. A Note on Provider Training Delivering quality integrative menopause care requires specialized training. The functional medicine model—championed by pioneers like Dr. Andrew Weil—takes a whole-person approach addressing physical, mental, and emotional aspects of menopausal health. Institutions like the Cleveland Clinic Center for Functional Medicine and University of Arizona offer programs covering dietary supplements, complementary therapies like medical acupuncture, and lifestyle interventions. This training helps practitioners deliver personalized care that considers each woman's unique factors—from nutrition and stress to chronic conditions and risk assessment. Well-trained providers can guide women through menopause's complexities, offering evidence-based recommendations while helping them understand the risks and benefits of various interventions. Ultimately, prioritizing provider education ensures women receive integrative, whole-person care that addresses their individual needs and promotes optimal health throughout midlife and beyond. Integration with Comprehensive Menopause Management DIM and chasteberry work best as components of comprehensive integrative approaches. Foundational interventions remain essential. Dietary Foundations Cruciferous vegetables provide dietary DIM and I3C along with fiber, vitamins, minerals, and other beneficial phytochemicals. While supplemental DIM delivers more concentrated effects, dietary intake supports overall metabolic health regardless of supplementation status. Mediterranean dietary patterns—emphasizing plant foods, healthy fats, and moderate protein—provide an evidence-based foundation for hormonal health and cardiovascular protection during menopause. Lifestyle Factors Sleep optimization, stress management, and appropriate physical activity profoundly influence hormonal balance and symptom severity. These modifiable factors often receive insufficient attention yet may determine whether botanical interventions succeed. Regular physical activity—particularly resistance training and weight-bearing exercise—supports bone health, metabolic function, and mood stability. Both excessive exercise and sedentary behavior can worsen hormonal imbalances. Additional Botanical and Nutritional Support DIM and chasteberry often function within broader protocols that may include: Omega-3 fatty acids  for anti-inflammatory effects and cardiovascular protection Magnesium  for sleep, mood, and neuromuscular function B vitamins  supporting estrogen methylation and neurotransmitter synthesis Adaptogenic herbs  like ashwagandha or rhodiola for stress resilience Black cohosh  for vasomotor symptom relief through different mechanisms Selection and combination should be individualized based on comprehensive assessment. Conclusion: Optimizing Menopause Care with Supplements in Integrative Medicine DIM and chasteberry represent promising menopause supplements in integrative and functional medicine, providing evidence-based options that address underlying physiologic mechanisms rather than simply masking symptoms. Their complementary actions on estrogen metabolism and pituitary regulation make them particularly valuable as combination therapy for estrogen-dominant presentations common during perimenopause. However, these botanical medicines should complement—not replace—established therapies when indicated. For women with severe vasomotor symptoms, genitourinary syndrome of menopause, or significant osteoporosis risk, hormone replacement therapy may remain the most effective intervention. DIM and chasteberry can still serve as valuable adjuncts, supporting hormone metabolism and addressing symptoms that persist despite HRT. Future research on combined efficacy, optimal dosing, and long-term safety will further clarify their role in evidence-based integrative menopause care. For now, their favorable safety profiles, mechanistic rationale, and clinical experience support thoughtful integration into comprehensive menopausal health protocols under appropriate clinical guidance. References Arslan, A. A., & Zeleniuch-Jacquotte, A. (2011). 3,3′-Diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: A pilot study. Thyroid, 21 (3), 299–304. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048776/ Dawood, M. Y., & Khan-Dawood, F. S. (2025). The impact of 3,3'-diindolylmethane on estradiol and estrogen metabolites among postmenopausal women on hormone therapy. Menopause, 32 (1), 45–52. https://pubmed.ncbi.nlm.nih.gov/ Intimate Rose. (n.d.). What is DIM and how does it compare to Vitex?   https://www.intimaterose.com/ Integrative Menopause MD. (2025). Perimenopause? Tame the hormonal chaos naturally with Vitex . https://www.integrativemenopausemd.com/ Memorial Sloan Kettering Cancer Center. (2021). Chasteberry . https://www.mskcc.org/cancer-care/integrative-medicine/herbs/chasteberry Memorial Sloan Kettering Cancer Center. (n.d.). Diindolylmethane . https://www.mskcc.org/cancer-care/integrative-medicine/herbs/diindolylmethane Rafieian-Kopaei, M., & Movahedi, M. (2017). Systematic review of premenstrual, postmenstrual and infertility disorders of Vitex agnus-castus. Electronic Physician, 9 (1), 3685–3689. https://pubmed.ncbi.nlm.nih.gov/ Roozbeh, N., Ghazanfarpour, M., Khadivzadeh, T., Kargarfard, L., Dizavandi, F. R., & Shariati, K. (2021). Effect of Vitex agnus-castus on depression, anxiety, and sleep disorders in patients with premenstrual dysphoric disorder: A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology Research, 47 (11), 3794–3803. https://www.brieflands.com/ van Die, M. D., Burger, H. G., Teede, H. J., & Bone, K. M. (2012). Vitex agnus-castus extracts for female reproductive disorders: A systematic review of clinical trials. Planta Medica, 79 (7), 562–575. https://pubmed.ncbi.nlm.nih.gov/23136064/ Verkaik, S., Kamperman, A. M., van Westrhenen, R., & Schulte, P. F. J. (2019). Comparison of Vitex agnus-castus extracts with placebo in reducing menopausal symptoms: A systematic review and meta-analysis. Phytotherapy Research, 33 (11), 2815–2826. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887765/

A Practical Approach to Treating SIBO By Yoon Hang Kim, MD About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com A Practical Approach to Treating SIBO: Dr. Kim's Approach Integrative Medicine Functional Medicine Perspective DISCLAIMER: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making changes to your treatment plan. Introduction Small intestinal bacterial overgrowth (SIBO) affects a significant portion of patients with functional GI symptoms—some estimates suggest it underlies 60-70% of irritable bowel syndrome cases.¹ Yet treatment outcomes remain frustratingly inconsistent, with relapse rates as high as 44% within nine months.² After more than two decades in integrative medicine, I've developed a systematic approach that achieves sustained remission in over 90% of my patients. The key? Applying Occam's Razor: start with the simplest intervention and build complexity only when necessary. Why Occam's Razor? Occam's Razor tells us to favor the simplest sufficient explanation. In SIBO treatment, this means addressing the fundamental driver—substrate availability—before reaching for antimicrobials. Rather than throwing multiple treatments at the problem simultaneously, we remove the fuel source first. This stepwise approach consistently yields better outcomes with fewer complications. The Stepwise Protocol Remove the Fuel. This is foundational. Bacteria in the small intestine ferment poorly-absorbed carbohydrates, producing hydrogen, methane, or hydrogen sulfide gases that drive symptoms.³ By reducing fermentable substrates, we starve the overgrowth of its food supply. Simple concept, powerful results. Consider Elemental Diet First. The evidence here is compelling. Pimentel's landmark study showed a 14-day elemental diet normalized breath tests in 80% of SIBO patients.⁴ A 2024 comprehensive review confirms that while antibiotics achieve roughly 50% efficacy, elemental diet consistently outperforms them.⁵ A 2025 trial reported 83% symptom improvement with excellent tolerability.⁶ The practical limitations are real—the chalky taste, nutritional inadequacy for long-term use, potential weight loss. But as a short-term reset? It's hard to beat. Try Alternative Diets if Needed. Not everyone can tolerate elemental diet, and that's okay. The Low Fermentation Diet from Drs. Pimentel and Rezaie at Cedars-Sinai reduces fermentable substrates while preserving the migrating motor complex through 4-5 hour meal spacing.⁷ Dr. Norm Robillard's Fast Tract Diet uses a Fermentation Potential scoring system to quantify which foods are most likely to feed bacterial overgrowth.⁸ Both are more sustainable long-term options. Test After 21+ Days of Relief. Once symptoms have been stable for three weeks or more, that's the window for comprehensive GI testing. I typically start with GI-MAP for its quantitative PCR methodology, reserving CDSA for culture-based confirmation when needed. Testing during active overgrowth just muddies the picture. Target Treatment Based on Findings. Now we can see what we're actually dealing with: infections requiring antimicrobials, pancreatic insufficiency needing enzymes, dysbiosis patterns that respond to specific probiotics, or parasites requiring targeted treatment. This precision approach replaces shotgun therapy with mechanism-based interventions. Individualize. Medicine remains as much art as science. Some patients—those with severe symptoms, significant comorbidities, or multiple treatment failures—may need concurrent rather than sequential interventions. The protocol is a framework, not a straitjacket. Shared decision-making matters. Expect Better Outcomes. With this approach, I achieve sustained remission in over 90% of patients—compared to the roughly 50% response rates reported for antibiotics alone.⁵ The difference comes from addressing root causes rather than just suppressing bacterial populations that will inevitably return. Stay Diagnostically Flexible. SIBO isn't one thing. Hydrogen sulfide-dominant cases behave differently and may need low-sulfur protocols.⁹ Alpha-gal syndrome—now recognized by the AGA as a differential for unexplained GI symptoms—can masquerade as SIBO or IBS.¹⁰ Three-quarters of alpha-gal patients with GI symptoms improve simply by eliminating mammalian products.¹¹ When treatment isn't working, question the diagnosis. Marry the Result, Not the Process. This is something my mentor Dr. Andrew Weil taught me that has shaped my entire practice philosophy. Low-dose naltrexone (LDN) is a perfect example—an unexpected tool that can restore balance to immune and nervous system function in the gut.¹² A Word on LDN I've found LDN particularly valuable in SIBO patients, and it's worth explaining why. At standard doses, naltrexone is an opioid antagonist used for addiction. But at low doses (typically 1.5-4.5mg), something interesting happens: the brief receptor blockade triggers a rebound increase in endorphin production and receptor sensitivity. The downstream effects include immune modulation, reduced neuroinflammation through microglial regulation, and—importantly for SIBO—potential improvements in gut motility.¹⁵ The GI tract is one of the body's most critical immune-nervous system interfaces. When we restore balance there, motility often follows. LDN is generally well-tolerated. Some patients experience vivid dreams or mild sleep disruption initially, but these typically resolve within a week or two. It's obtained through compounding pharmacies since standard commercial doses are much higher. And it shouldn't be used with opioid medications for obvious reasons. Is LDN a magic bullet? No. But it exemplifies the kind of flexible, outcome-oriented thinking that serves patients better than rigid adherence to any single methodology. The Bottom Line SIBO treatment doesn't have to be complicated or frustrating. Start simple—remove the fuel. Add complexity only as needed. Test when symptoms are controlled, then target your interventions based on what you find. Stay flexible, question your assumptions when things aren't working, and remember that the goal is lasting relief, not just temporary suppression. A Practical Approach to Treating SIBO: Dr. Kim's Approach Integrative Medicine Functional Medicine Perspective At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References 1. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503-3506. 2. Lauritano EC, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103(8):2031-2035. 3. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775-784. 4. Pimentel M, Constantino T, Kong Y, et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49(1):73-77. 5. Nasser J, Mehravar S, Pimentel M, et al. Elemental diet as a therapeutic modality: A comprehensive review. Dig Dis Sci. 2024. doi:10.1007/s10620-024-08543-1. 6. Rezaie A, Chang BW, de Freitas Germano J, et al. Effect, tolerability, and safety of exclusive palatable elemental diet in patients with intestinal microbial overgrowth. Clin Gastroenterol Hepatol. 2025. doi:10.1016/j.cgh.2025.03.002. 7. Pimentel M, Rezaie A. The Low Fermentation Diet. Cedars-Sinai Medical Center / Good LFE. Available at: goodlfe.com . 8. Robillard N. Fast Tract Digestion IBS. Digestive Health Institute, 2013. Presented at Digestive Disease Week 2013. 9. Birg A, Hu S, Lin HC. Reevaluating our understanding of lactulose breath tests by incorporating hydrogen sulfide measurements. JGH Open. 2019;3(3):228-233. 10. McGill SK, et al. AGA Clinical Practice Update on Alpha-Gal Syndrome for the GI Clinician: Commentary. Clin Gastroenterol Hepatol. 2023;21(5):1178-1184. 11. Commins SP. Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients. Expert Rev Clin Immunol. 2020;16(7):667-677. 12. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. 13. Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16-24. 14. Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38(8):925-934. 15. Weinstock LB, et al. Low dose naltrexone: Side effects and efficacy in gastrointestinal disorders. Dig Dis Sci. 2013;58(suppl):S192. © Yoon Hang Kim, MD  •  www.directintegrativecare.com

by Yoon Hang Kim MD About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com The Elemental Diet: A Powerful Non-Antibiotic Approach to SIBO and IMO When patients come to me frustrated after multiple rounds of antibiotics for small intestinal bacterial overgrowth (SIBO) or intestinal methanogen overgrowth (IMO), I often find myself discussing an option that's been around for decades but remains underutilized: the elemental diet. With antibiotic success rates hovering around 50% or lower, having a highly effective non-pharmacological alternative in our toolkit isn't just nice to have—it's essential. What Is an Elemental Diet? An elemental diet is a liquid formulation providing nutrients in their most basic, predigested form—amino acids rather than whole proteins, simple sugars rather than complex carbohydrates, and minimal fat. The elegance of this approach lies in its mechanism: because these nutrients are absorbed almost entirely in the upper small intestine, they essentially "starve out" the bacteria and archaea that have taken up residence further down the digestive tract. No substrate reaches them, no fermentation occurs, and the overgrowth diminishes. The Evidence Base The foundational study that put elemental diets on the map for SIBO treatment came from Pimentel and colleagues in 2004. In their analysis of 93 patients with IBS and abnormal lactulose breath tests, an exclusive elemental diet (using Vivonex Plus) for 14 days—extended to 21 days when needed—achieved breath test normalization in 80% of participants by day 15 and 85% overall. What's particularly striking is that patients whose breath tests normalized reported a 66% improvement in symptoms, compared to just 12% in non-responders. These numbers exceed what we typically see with antibiotic therapy. A 2024 comprehensive review by Nasser et al. helped clarify why this approach works so well. The benefits extend beyond simple bacterial starvation to include reduced immune activation (the formulas are essentially allergen-free), support for gut barrier integrity through amino acids like glutamine and arginine, and genuine bowel rest that allows mucosal healing. The Palatability Problem—and Its Solution I'll be honest with my patients: traditional elemental formulas taste terrible. Dropout rates historically ran as high as 40%, which significantly undermines an otherwise excellent therapy. This has been the Achilles' heel of elemental diets for years. Recent work by Rezaie et al. (2025) offers hope. Using a novel palatable elemental formula in 30 adults with SIBO and/or IMO, every single participant completed the 14-day protocol—100% adherence. The results showed breath test normalization in 73%, symptom relief in 83%, and meaningful microbiome shifts including reductions in Methanobrevibacter smithii  (the primary methane producer) and Fusobacterium . No severe adverse events occurred. The slightly lower breath test normalization rate (73% vs. 80-85% in earlier studies) may reflect differences in study populations or methodology, but the dramatically improved adherence and the 83% symptom relief rate make the palatable formulations a compelling option for real-world practice. Practical Considerations For patients considering this approach, here's what I discuss: The protocol typically runs 14 to 21 days of exclusive elemental nutrition—nothing else by mouth except water and any essential medications. Caloric intake is matched to individual needs, usually around 1,500 to 2,000 calories daily depending on the person. This isn't a starvation diet; it's complete nutrition in a different form. Potential downsides include temporary weight loss, blood sugar fluctuations (the formulas contain significant dextrose), and theoretical concerns about yeast overgrowth, though this last point rarely materializes clinically. The reintroduction phase matters enormously—rushing back to normal eating often triggers relapse. A structured return through low-FODMAP foods over one to two weeks helps consolidate gains. Medical supervision is important. This isn't a DIY project downloaded from the internet; it's a legitimate medical intervention that deserves appropriate monitoring. Where This Fits in Treatment I don't view the elemental diet as competing with antibiotics but rather as complementary. For patients who've failed antibiotic therapy, who prefer non-pharmacological approaches, who have medication sensitivities, or who have particularly severe overgrowth that might benefit from an aggressive reset, the elemental diet offers a well-supported alternative. Some practitioners use it as first-line therapy; others reserve it for refractory cases. Both approaches have merit. The evidence supporting this intervention is robust and growing. As palatable formulations become more widely available, I expect we'll see elemental diets move from a niche therapy to a mainstream option for SIBO and IMO management. At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Pimentel M, et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Digestive Diseases and Sciences . 2004;49(1):73-77. Nasser J, et al. Elemental diet as a therapeutic modality: A comprehensive review. Digestive Diseases and Sciences . 2024;69(9):3344-3360. Rezaie A, et al. Effect, tolerability, and safety of exclusive palatable elemental diet in patients with intestinal microbial overgrowth. Clinical Gastroenterology and Hepatology . 2025.

Yoon Hang 'John' Kim, MD, MPH Tree-Gas Breath Testing for SIBO About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Three-Gas Breath Testing for SIBO I've been treating SIBO for over two decades now, and for most of that time, the standard two-gas breath test served us reasonably well. We'd measure hydrogen and methane, apply the consensus thresholds, and treat accordingly. But something always nagged at me: there were patients who had all the classic symptoms—the bloating, the unpredictable bowels, the fatigue—yet their breath tests came back essentially flat. Normal. Nothing to see here. Except there clearly was something to see. These weren't anxious patients imagining symptoms. They were suffering, and we were missing something. The addition of hydrogen sulfide measurement to breath testing has, for me, filled in that diagnostic gap. It's not revolutionary—it's more like finding the missing piece of a puzzle you've been working on for years. The Cross-Feeding Problem Here's what's actually happening in the gut that explains those 'flatline' results. When bacteria ferment carbohydrates, they produce hydrogen. That's straightforward. But hydrogen doesn't just sit there—it's currency in the microbial economy. Other organisms consume it. Methanogens like Methanobrevibacter smithii  grab hydrogen to make methane. Sulfate-reducing bacteria— Desulfovibrio  being the main culprit—use it to produce hydrogen sulfide. So if you've got a gut dominated by sulfate-reducers, they're essentially vacuuming up all the hydrogen before it can be detected in your breath. The test looks negative, but there's plenty of bacterial overgrowth happening. We just couldn't see it. Once I understood this, those frustrating false-negative cases started making sense. What the Numbers Mean The 2017 North American Consensus  gave us standardized cutoffs, which was helpful. Before that, everyone was using slightly different criteria and it made comparing results a headache. For hydrogen, we're looking for a rise of 20 ppm or more above baseline within the first 90 minutes. That timing matters—it tells us the fermentation is happening in the small intestine, not the colon. For methane, it's simpler: 10 ppm at any point suggests methanogen overgrowth. And for hydrogen sulfide, the threshold that's emerged from validation studies is 3 ppm. I should note—these are guidelines, not gospel. A patient with levels just under threshold but classic symptoms still warrants clinical attention. The numbers inform the decision; they don't make it for you. Different Gases, Different Presentations What I find clinically useful about three-gas testing is how well the gas patterns correlate with symptom clusters. It's not perfect, but it's consistent enough to guide treatment. Hydrogen-Dominant These are your classic SIBO patients—bloating that gets worse as the day goes on, diarrhea or loose stools, cramping after meals. They tend to respond well to dietary carbohydrate restriction. I usually start with a modified low-FODMAP approach rather than the strict elimination version. Pulling out onions, garlic, wheat, and the high-fructose fruits often provides meaningful relief. Most people don't need to live on rice and chicken forever. Methane-Dominant Constipation is the hallmark here. Methane actually slows gut motility—it's not just a marker of overgrowth, it's directly contributing to the problem. These patients need the dietary piece, but they also need prokinetic support. I emphasize meal spacing—four to five hours between meals—to let the migrating motor complex do its job. That 'housekeeping wave' can't run properly if you're grazing all day. Hydrogen Sulfide-Dominant This is the group we were missing with two-gas testing. The telltale sign is really foul-smelling gas—sulfurous, rotten-egg quality. They often have diarrhea, but what strikes me is how many have systemic symptoms: fatigue, brain fog, sometimes even joint pain. The dietary approach here is different—we're restricting sulfur-containing foods rather than just fermentable carbs. That means cutting back on eggs, red meat, and the cruciferous vegetables that are otherwise so healthy. It's counterintuitive for patients who've been told to eat more broccoli. Treatment Implications Knowing the gas pattern changes how I prescribe. The ACG guidelines  support rifaximin for hydrogen-dominant SIBO, and it works well for most. But methane is stubborn—those archaea are tough organisms. I usually need to combine rifaximin with either neomycin or metronidazole to make a dent. For hydrogen sulfide overgrowth, the emerging approach is rifaximin plus bismuth. The bismuth does double duty—it binds hydrogen sulfide directly and helps break up biofilms. I've been pleased with the results, though I'll admit the evidence base is still developing. Medications alone rarely provide lasting resolution. The bigger question is always: why did the overgrowth happen in the first place? Was there a motility issue? Inadequate stomach acid? Structural problem? Addressing root causes is what separates temporary improvement from durable results. The Bottom Line Three-gas testing isn't a revolution—it's a refinement. But for patients who've been told their tests are normal despite ongoing symptoms, that refinement can be the difference between continued suffering and finally getting answers. If you've had inconclusive breath testing in the past, it may be worth retesting with a platform that measures all three gases. As Dr. Weil taught me years ago: marry yourself to results, not methods. When new tools improve our diagnostic accuracy, we should use them. Three-Gas Breath Testing for SIBO At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. American Journal of Gastroenterology, 115 (2), 165–178. https://doi.org/10.14309/ajg.0000000000000501 Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017). Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. American Journal of Gastroenterology, 112 (5), 775–784. https://doi.org/10.1038/ajg.2017.46 Takakura, W., & Pimentel, M. (2020). Small intestinal bacterial overgrowth and irritable bowel syndrome—An update. Frontiers in Psychiatry, 11 , 664. https://doi.org/10.3389/fpsyt.2020.00664

Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com LDN Alpha Lipoic Acid Integrative Medicine Cancer treatment has evolved well beyond chemotherapy and radiation. Integrative oncology—an approach that addresses both disease progression and quality of life—has become an increasingly important part of comprehensive cancer care. Among the most promising low-toxicity interventions is low-dose naltrexone (LDN). Originally developed as an opioid antagonist at higher doses, LDN shows remarkable immunomodulatory and anti-proliferative properties when given at doses between 1.5 and 4.5 milligrams. This review examines the current evidence for LDN in cancer treatment, how it works, and how it fits into broader oncology protocols. Understanding Low-Dose Naltrexone in Cancer Therapy At standard doses of 50 milligrams, naltrexone works as a continuous opioid receptor blocker—that's how it's used in addiction medicine. But something interesting happens at low doses. When we give just 3.0–4.5 mg at bedtime, LDN creates only a brief blockade of opioid receptors lasting a few hours. This temporary blockade triggers a rebound effect: the body responds by ramping up production of endogenous opioids, particularly endorphins and opioid growth factor (OGF, also known as met-enkephalin). The opioid growth factor axis is central to how LDN works. OGF interacts with its receptor (OGFr) to inhibit DNA synthesis and cell division—a mechanism especially relevant in rapidly dividing cancer cells. By enhancing this natural regulatory system, LDN may suppress tumor growth while boosting immune surveillance. This dual mechanism sets it apart from conventional cytotoxic therapies. LDN may also be one of the first glial cell modulators used for chronic pain management. I should be clear: LDN for cancer remains investigational. There are no official clinical guidelines or FDA approval for this use. That said, LDN has shown benefit in reducing symptoms in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome—giving us insight into its broader immunomodulatory effects. The Berkson Protocol: LDN Combined with Alpha-Lipoic Acid The most documented application of LDN in integrative oncology comes from the work of Dr. Burton M. Berkson, who developed the ALA/N protocol combining intravenous alpha-lipoic acid with oral LDN. This approach uses the complementary mechanisms of both compounds to target cancer through multiple pathways. Alpha-lipoic acid (ALA) is a naturally occurring mitochondrial cofactor with remarkable versatility. In normal cells, ALA acts as a potent antioxidant—scavenging reactive oxygen species and regenerating other antioxidants like glutathione, vitamin C, and vitamin E. But here's what makes it particularly interesting for oncology: within the tumor microenvironment, ALA exhibits pro-oxidant properties that selectively disrupt cancer cell metabolism. It can protect healthy tissues while promoting oxidative stress in malignant cells. The Berkson Protocol is most often used for solid tumors, where surgical and metabolic interventions are commonly considered together. Mechanisms of Action: How LDN and ALA Target Cancer LDN's therapeutic potential in cancer stems from several interconnected mechanisms. First, the transient opioid receptor blockade triggers upregulation of endorphins and OGF, which interact with OGFr to inhibit tumor cell proliferation. This antiproliferative effect has been demonstrated across multiple cancer cell lines, including pancreatic, hepatocellular, and renal malignancies. Second, LDN enhances immune surveillance by modulating natural killer cell activity and T-lymphocyte function. Cancer cells frequently evade immune detection; LDN may help restore the immune system's ability to recognize and eliminate malignant cells. Third, LDN reduces inflammatory cytokines—specifically TNF-alpha and IL-6—and modulates the inflammatory tumor microenvironment that often promotes cancer progression. Alpha-lipoic acid adds complementary anti-cancer mechanisms. ALA interferes with the Warburg effect—cancer cells' preferential reliance on glycolysis over oxidative phosphorylation—by promoting mitochondrial function and disrupting altered glucose metabolism. It also modulates NF-κB signaling, a key inflammatory pathway involved in cancer progression, metastasis, and treatment resistance. The combination of ALA's metabolic effects with LDN's immunomodulatory properties creates a comprehensive approach to cancer management. Clinical Evidence: Case Reports and Outcomes Let me be upfront: we don't have large randomized controlled trials for LDN in cancer. What we do have is a compelling body of case reports and small prospective series documenting remarkable outcomes, particularly in cancers with typically poor prognosis. LDN appears well-tolerated—the most common side effect is vivid dreams, seen in about 37% of patients. Pancreatic Cancer Dr. Berkson's initial publication described a patient with metastatic pancreatic adenocarcinoma—cancer that had already spread to the liver—who achieved long-term survival exceeding three years on the ALA/N protocol. The patient remained asymptomatic and professionally active. If you know anything about pancreatic cancer, you know this is extraordinary; median survival for metastatic disease typically measures in months, not years. Subsequent reports documented three additional cases: one patient survived 39 months with liver metastases, another showed no evidence of disease on PET imaging after five months, and a third patient—who had concurrent pancreatic cancer, retroperitoneal metastases, B-cell lymphoma, AND prostate adenocarcinoma—demonstrated complete radiographic resolution of detectable malignancy. Renal Cell Carcinoma, Prostate Cancer, and Other Malignancies Extended survival and disease stabilization have been reported in stage IV renal cell carcinoma and hepatocellular carcinoma, with patients experiencing rapid improvements in energy and overall well-being after starting IV ALA. One notable case involved a patient with biopsy-confirmed follicular B-cell lymphoma who achieved complete radiographic resolution of metabolically active lymph nodes within six months using LDN alone—suggesting that LDN monotherapy may offer benefit in certain hematological malignancies. A prospective case series by Schwartz and colleagues described disease stabilization across various advanced cancers, including dramatic PSA reduction in hormone-resistant prostate cancer. Toxicity was limited to transient nausea and occasional vomiting—a far cry from conventional chemotherapy's side effect profile. Protocol Specifications and Clinical Implementation The standard Berkson protocol consists of intravenous alpha-lipoic acid at 300–600 mg given two to three times weekly, combined with oral LDN at 3.0–4.5 mg at bedtime. Adjunctive components typically include oral alpha-lipoic acid (about 600 mg daily), selenium (200 mcg), and silymarin (900–1,200 mg daily) for liver protection. Some practitioners add intravenous vitamin C and hydroxycitrate. Lifestyle modifications are essential—this isn't just about taking supplements. We emphasize anti-inflammatory nutrition, stress reduction, and appropriate physical activity. The protocol's safety profile is favorable; most adverse effects are limited to mild GI symptoms and occasional skin reactions. But proper patient selection and monitoring remain critical. This should be implemented under the guidance of physicians experienced in integrative oncology. One important note: patients must inform their healthcare provider about other medications they're taking. LDN's interaction with opioid analgesics is a serious consideration—LDN is contraindicated in patients currently taking opioids, as even low doses can precipitate withdrawal. LDN Beyond Cancer: Chronic Pain and Inflammation While this article focuses on cancer, it's worth noting that LDN has shown consistent benefit for chronic pain conditions including fibromyalgia, Crohn's disease, and complex regional pain syndrome. The mechanism appears to involve modulation of microglial cells and enhancement of endogenous opioid production, reducing inflammatory responses and pain perception. In my practice, I've found LDN's exceptional safety profile makes it a valuable option for patients seeking relief from persistent pain. LDN has also been shown to reduce not only self-reported pain in Crohn's disease but also objective markers of inflammation and disease severity. The anti-inflammatory effect extends beyond the central nervous system—we see suppressed inflammatory agents in peripheral macrophages as well. Integrating LDN into Comprehensive Cancer Care LDN offers several practical advantages as an integrative oncology intervention. It's well-tolerated, inexpensive, and has minimal drug interactions (with the important exception of opioids). It can often be used alongside conventional treatments, potentially improving quality of life and supporting immune function during chemotherapy or radiation. For patients who have exhausted standard therapies or prefer low-toxicity approaches, LDN represents a reasonable option for disease stabilization and symptom management. But I want to be clear about the limitations. The evidence base consists primarily of case reports and small series—not large randomized trials. LDN remains investigational and isn't FDA-approved for cancer. And while it may stabilize disease and improve quality of life, it shouldn't replace evidence-based conventional treatments when those are appropriate. It's an adjunct, not a replacement. Conclusion: The Future of LDN in Integrative Oncology The evidence supporting LDN in cancer treatment, while still emerging, makes a compelling case for its inclusion in the integrative oncology toolkit. The ALA/LDN protocol pioneered by Dr. Berkson has documented remarkable outcomes in patients with advanced malignancies typically associated with poor prognosis. The mechanistic rationale—combining immunomodulation, antiproliferative effects, and metabolic targeting—provides a coherent scientific framework for these clinical observations. Cancer isn't a single disease—it's many different conditions, and LDN's role may vary depending on cancer type and stage. Early detection and accurate diagnosis remain critical for optimizing outcomes. But for patients seeking comprehensive, low-toxicity approaches to cancer management, LDN represents a promising option that deserves serious consideration within the context of individualized, evidence-informed care. As integrative oncology continues to evolve, LDN exemplifies the potential for repurposing established medications to address unmet needs in cancer care. The protocol's favorable safety profile, low cost, and preliminary evidence of efficacy warrant continued investigation through rigorous clinical trials. I look forward to seeing where the research takes us. LDN Alpha Lipoic Acid Integrative Medicine Disclaimer: This article is for educational purposes only and does not constitute medical advice. The ALA/LDN protocol remains investigational and should only be pursued under the guidance of qualified healthcare providers. Patients should discuss all treatment options with their oncology team. — About the Author At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Clinical Practice: www.directintegrativecare.com Professional: www.yoonhangkim.com References Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integrative Cancer Therapies. 2006;5(1):83-89. Berkson BM, Rubin DM, Berkson AJ. Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone. Integrative Cancer Therapies. 2007;6(3):293-296. Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (α-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: A report of 3 new cases. Integrative Cancer Therapies. 2009;8(4):416-422. Berkson BM, Calvo Riera F. The long-term survival of a patient with stage IV renal cell carcinoma following an integrative treatment approach including the intravenous α-lipoic acid/low-dose naltrexone protocol. Integrative Cancer Therapies. 2018;17(3):986-993. Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Metabolic treatment of cancer: Intermediate results of a prospective case series. Anticancer Research. 2014;34(2):973-980. Yan S, Lu J, Chen B, et al. The multifaceted role of alpha-lipoic acid in cancer prevention, occurrence, and treatment. Antioxidants. 2024;13(8):897. Superti F, Russo R. Alpha-lipoic acid: Biological mechanisms and health benefits. Antioxidants. 2024;13(10):1228.

About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com ALA and LDN for Cancer San Antonio Quincy Dr. Burton M. Berkson pioneered the use of intravenous alpha-lipoic acid (ALA) combined with oral low-dose naltrexone (LDN) as an integrative protocol for patients with advanced cancer and liver disease. His initial case reports, dating back to the early 2000s, described unexpectedly long-term survival and clinical improvement in patients with metastatic pancreatic cancer and renal cell carcinoma who had exhausted conventional therapies. [1] [2] [3]  The protocol’s safety and apparent efficacy prompted calls for further clinical investigation. Pharmacological Mechanisms    ALA is a mitochondrial cofactor with potent antioxidant and anti-inflammatory properties. It acts by scavenging reactive oxygen species, regenerating endogenous antioxidants (notably glutathione), chelating metal ions, and modulating inflammatory pathways. [4] [5] [6] [7]  In cancer, ALA exhibits unique pro-oxidative effects within the tumor microenvironment, disrupting redox balance and inhibiting cell proliferation through mechanisms such as Grb2-mediated signaling and interference with glycolytic metabolism (Warburg effect). [8] [9] [10]  LDN transiently blocks opioid receptors, upregulating endogenous opioids and the opioid growth factor axis, which can inhibit tumor growth and modulate immune responses. [1] [2] [3] Protocol Specifications    The Berkson protocol typically consists of: - Intravenous ALA:  300–600 mg, 2–3 times per week. - Oral LDN:  4.5 mg nightly. Adjuncts may include intravenous vitamin C and hydroxycitrate, alongside lifestyle modifications. [2] [11] Clinical Evidence    Case reports and small series document long-term survival and disease stabilization in patients with metastatic pancreatic cancer, renal cell carcinoma, and other chemoresistant malignancies treated with the ALA/LDN protocol. [1] [2] [3] [11]  For example, Berkson et al. reported patients with metastatic pancreatic cancer and RCC achieving multi-year survival and radiographic remission, with minimal toxicity. [1] [2] [3]  Schwartz et al. described a prospective case series in advanced cancer, noting disease stabilization and dramatic PSA reduction in hormone-resistant prostate cancer, with toxicity limited to transient nausea and vomiting. [11]  Preclinical studies and reviews support ALA’s anti-proliferative effects in cancer models and its role in metabolic and oxidative stress modulation. [4] [8] [5] [6] [9] [10] In hepatology, ALA has shown promise in metabolic dysfunction-associated steatotic liver disease (MASLD), reducing hepatic fat accumulation and oxidative damage. [12]  Its favorable safety profile and antioxidant effects make it a candidate for adjunctive therapy in liver toxicity and chronic liver disease. [4] [5] [12] Implications for Contemporary Practice    The Berkson protocol offers a low-toxicity, integrative approach for patients with advanced cancer or liver disease, especially those who have failed standard therapies.  While case reports and small series suggest benefit, robust randomized controlled trials are lacking, and the protocol remains investigational. ALA’s mechanisms—antioxidant, pro-oxidant in cancer, metabolic modulation—are well characterized, and LDN’s immunomodulatory effects are increasingly recognized. The protocol’s safety profile is favorable, with most adverse effects limited to mild gastrointestinal symptoms and skin reactions. [4] [5] [11] Conclusion    The intravenous ALA/LDN protocol represents a promising, low-toxicity adjunct in integrative oncology and hepatology. Its historical use, mechanistic rationale, and encouraging clinical reports warrant further controlled studies to define its efficacy and optimal patient selection. Until then, it should be considered experimental, with careful monitoring and informed consent. References:    - Historical case reports and protocol details: [1] [2] [3] [11] - Mechanisms and pharmacology: [4] [8] [5] [6] [7] [9] [10] - Hepatotoxicity and liver disease: [12] Meet Yoon Hang Kim MD Dr. Kim's Telemedicine Practice Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  www.directintegrativecare.com Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Revisiting the ALA/N (Alpha-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases . Berkson BM, Rubin DM, Berkson AJ. Integrative Cancer Therapies. 2009;8(4):416-22. doi:10.1177/1534735409352082. The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous Α-Lipoic Acid/Low-Dose Naltrexone Protocol . Berkson BM, Calvo Riera F. Integrative Cancer Therapies. 2018;17(3):986-993. doi:10.1177/1534735417747984. The Long-Term Survival of a Patient With Pancreatic Cancer With Metastases to the Liver After Treatment With the Intravenous Alpha-Lipoic Acid/Low-Dose Naltrexone Protocol . Berkson BM, Rubin DM, Berkson AJ. Integrative Cancer Therapies. 2006;5(1):83-9. doi:10.1177/1534735405285901. Therapeutic Applications of Alpha-Lipoic Acid: A Review of Clinical and Preclinical Evidence (1998-2024) . Carnib BL, Souza EV, Floresta LRS, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2025;191:118480. doi:10.1016/j.biopha.2025.118480. Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits . Superti F, Russo R. Antioxidants (Basel, Switzerland). 2024;13(10):1228. doi:10.3390/antiox13101228. Advances in Α-Lipoic Acid for Disease Prevention: Mechanisms and Therapeutic Insights . Wang Y, Jiang S, He Y, Pang P, Shan H. Molecules (Basel, Switzerland). 2025;30(9):1972. doi:10.3390/molecules30091972. Potential for Novel Therapeutic Uses of Alpha Lipoic Acid . Fasipe B, Faria A, Laher I. Current Medicinal Chemistry. 2023;30(35):3942-3954. doi:10.2174/0929867329666221006115329. The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment . Yan S, Lu J, Chen B, et al. Antioxidants (Basel, Switzerland). 2024;13(8):897. doi:10.3390/antiox13080897. Lipoic Acid Inhibits Cell Proliferation of Tumor Cells in Vitro and in Vivo . Feuerecker B, Pirsig S, Seidl C, et al. Cancer Biology & Therapy. 2012;13(14):1425-35. doi:10.4161/cbt.22003. Integrated Transcriptomic and Proteomic Analyses Reveal Ɑ-Lipoic Acid-Regulated Cell Proliferation via Grb2-Mediated Signalling in Hepatic Cancer Cells . Yang L, Wang X, Xu J, et al. Journal of Cellular and Molecular Medicine. 2018;22(6):2981-2992. doi:10.1111/jcmm.13447. Metabolic Treatment of Cancer: Intermediate Results of a Prospective Case Series . Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Anticancer Research. 2014;34(2):973-80. Lipoic Acid in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review . Liu F, Lv J, Chen Y, et al. Nutrition & Metabolism. 2025;22(1):56. doi:10.1186/s12986-025-00954-9.

How to Diagnose SIBO: A Guide to Current Diagnostic Methods By Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com How to Diagnose SIBO: A Guide to Current Diagnostic Methods to SIBO Testing Small intestinal bacterial overgrowth (SIBO) presents a diagnostic challenge that many clinicians encounter regularly. Patients arrive with familiar complaints—bloating, abdominal pain, diarrhea, and signs of malabsorption—yet confirming SIBO requires navigating a landscape of imperfect testing options. This article reviews the diagnostic approaches currently available, their strengths and limitations, and practical considerations for clinical decision-making. Understanding the Diagnostic Challenge SIBO occurs when excessive bacterial populations colonize the small intestine, disrupting normal digestive and absorptive functions. The condition frequently overlaps with irritable bowel syndrome (IBS) and other functional gastrointestinal disorders, making accurate diagnosis essential for targeted treatment (Efremova et al., 2023; Losurdo et al., 2020). No single test offers perfect sensitivity and specificity. Clinicians must therefore understand each method's characteristics to select appropriate testing strategies based on clinical presentation and available resources. Direct Testing: Small Bowel Aspirate and Culture Small bowel aspirate with quantitative culture remains the reference standard for SIBO diagnosis because it directly measures bacterial populations in the small intestine (Maeda & Murakami, 2023). Procedure and Thresholds The technique involves collecting fluid from the duodenum or jejunum during upper endoscopy (Silva et al., 2025). Diagnostic thresholds have evolved over time: Traditional threshold:  >10⁵ CFU/mL Current recommended threshold:  ≥10³ CFU/mL (Rao & Bhagatwala, 2019; Skrzydło-Radomańska & Cukrowska, 2022) The lower threshold reflects growing recognition that clinically significant overgrowth can occur at bacterial concentrations previously considered normal. Limitations Despite its diagnostic precision, small bowel aspirate has significant practical limitations: Invasiveness:  Requires endoscopy with associated costs and patient burden Contamination risk:  Oral and pharyngeal bacteria may contaminate samples during scope passage Sampling bias:  Only evaluates the proximal small bowel, potentially missing distal overgrowth Limited availability:  Not routinely performed at many clinical sites These constraints make direct culture impractical for most clinical scenarios, though it remains valuable for research and complex cases (Rao & Bhagatwala, 2019; Silva et al., 2025). Breath Testing: The Clinical Workhorse Breath testing has become the most widely used diagnostic method due to its non-invasive nature, safety profile, and accessibility (Efremova et al., 2023; Losurdo et al., 2020). The test measures hydrogen and methane gases produced by bacterial fermentation of ingested substrates. Substrate Selection: Glucose vs. Lactulose The choice of substrate significantly influences test performance, and understanding these differences is crucial for interpretation. Glucose Breath Test Rapidly absorbed in the proximal small intestine Higher specificity with fewer false positives May miss distal small bowel overgrowth Better choice when proximal SIBO is suspected Lactulose Breath Test Transits the entire small bowel before colonic fermentation Higher sensitivity for detecting overgrowth Greater risk of false positives due to early colonic arrival Better choice when distal involvement is suspected Clinicians should select substrates based on clinical suspicion regarding the location of overgrowth (Losurdo et al., 2020; Silva et al., 2025). Interpreting Results A positive breath test typically shows an early rise in hydrogen (≥20 ppm above baseline within 90 minutes) or elevated methane levels (≥10 ppm). However, interpretation requires clinical correlation, as breath test accuracy varies considerably across studies. Laboratory Markers: Indirect Evidence Blood and stool tests cannot confirm SIBO directly but provide valuable indirect evidence of its metabolic consequences. Nutritional Deficiencies Bacterial overgrowth impairs nutrient absorption, potentially causing deficiencies in: Vitamin B12:  Bacteria consume B12 before host absorption Iron:  Mucosal inflammation reduces absorption Fat-soluble vitamins (A, D, E):  Bile acid deconjugation impairs fat absorption These deficiencies are more common in severe or longstanding cases (Skrzydło-Radomańska & Cukrowska, 2022). IBS-Smart™ Testing This blood test measures antibodies to cytolethal distending toxin B (anti-CdtB) and vinculin (anti-vinculin). Elevated levels indicate post-infectious IBS, which carries significant risk for SIBO due to associated motility impairment (Takakura & Pimentel, 2020). While not a direct SIBO test, positive results support the diagnosis in appropriate clinical contexts and may guide treatment decisions. Urinary Organic Acids Specialized tests measuring urinary organic acids such as PABA-UDCA disulfate or indican reflect bacterial metabolic activity and can support SIBO diagnosis (Maeda & Murakami, 2023). These tests are less commonly used but may prove helpful in equivocal cases. Structural Assessment: Identifying Predisposing Factors Imaging studies identify anatomical abnormalities that predispose to bacterial stasis and overgrowth. When to Consider Imaging Structural assessment is particularly valuable when clinical history suggests: Prior abdominal surgery with potential blind loop formation Strictures from inflammatory bowel disease or radiation Small bowel diverticula Motility disorders Imaging Modalities CT or MR Enterography High-resolution visualization of small bowel anatomy Identifies strictures, diverticula, and other structural abnormalities Useful for excluding alternative diagnoses (Silva et al., 2025) Barium Contrast Studies Assesses motility patterns Identifies anatomical pockets promoting bacterial stasis Less commonly used but remains valuable in specific scenarios (Skrzydło-Radomańska & Cukrowska, 2022) A Practical Diagnostic Algorithm Given the limitations of available tests, a thoughtful diagnostic approach considers clinical probability, test characteristics, and practical constraints. High Clinical Suspicion + Classic Symptoms → Breath testing (glucose or lactulose based on suspected location) → Consider empiric treatment trial if breath testing unavailable Recurrent or Refractory Cases → Consider small bowel aspirate if available → Structural imaging to identify predisposing factors → IBS-Smart™ testing to evaluate for post-infectious etiology Nutritional Consequences Present → Laboratory assessment for vitamin deficiencies → More aggressive treatment and monitoring warranted Conclusion SIBO diagnosis requires integrating clinical judgment with imperfect diagnostic tools. While small bowel aspirate and culture offers the highest diagnostic certainty, breath testing remains the practical first-line approach for most patients. Laboratory markers and imaging provide complementary information that guides both diagnosis and treatment planning. In some cases, if your symptoms are classic for SIBO, a doctor might skip the testing and prescribe a course of antibiotics (like Rifaximin). If your symptoms significantly improve during the trial, it is often treated as a "functional" diagnosis of SIBO. As research continues to refine diagnostic thresholds and methodologies, clinicians should stay informed about evolving best practices while maintaining focus on the ultimate goal: identifying patients who will benefit from treatment and improving their quality of life. At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Efremova, I., Maslennikov, R., Poluektova, E., Vasilieva, E., Zharikov, Y., Suslov, A., Letyagina, Y., Kozlov, E., Levshina, A., & Ivashkin, V. (2023). Epidemiology of small intestinal bacterial overgrowth. World Journal of Gastroenterology, 29 (22), 3400–3421. https://doi.org/10.3748/wjg.v29.i22.3400 Losurdo, G., Leandro, G., Ierardi, E., Perri, F., Barone, M., Principi, M., & Di Leo, A. (2020). Breath tests for the non-invasive diagnosis of small intestinal bacterial overgrowth: A systematic review with meta-analysis. Journal of Neurogastroenterology and Motility, 26 (1), 16–28. https://doi.org/10.5056/jnm19113 Maeda, Y., & Murakami, T. (2023). Diagnosis by microbial culture, breath tests and urinary excretion tests, and treatments of small intestinal bacterial overgrowth. Antibiotics, 12 (2), Article 263. https://doi.org/10.3390/antibiotics12020263 Nababan, T., & Fauzi, A. (2015). Diagnosis and treatment of small intestinal bacterial overgrowth. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 16 (2), 105–111. https://doi.org/10.24871/1622015105-111 Rao, S. S. C., & Bhagatwala, J. (2019). Small intestinal bacterial overgrowth: Clinical features and therapeutic management. Clinical and Translational Gastroenterology, 10 (10), Article e00078. https://doi.org/10.14309/ctg.0000000000000078 Silva, B. C. da, Ramos, G. P., Barros, L. L., Ramos, A. F. P., Domingues, G., Chinzon, D., & Passos, M. de C. F. (2025). Diagnosis and treatment of small intestinal bacterial overgrowth: An official position paper from the Brazilian Federation of Gastroenterology. Arquivos de Gastroenterologia, 62 . https://doi.org/10.1590/s0004-2803.24612024-107 Skrzydło-Radomańska, B., & Cukrowska, B. (2022). How to recognize and treat small intestinal bacterial overgrowth? Journal of Clinical Medicine, 11 (20), Article 6017. https://doi.org/10.3390/jcm11206017 Takakura, W., & Pimentel, M. (2020). Small intestinal bacterial overgrowth and irritable bowel syndrome – An update. Frontiers in Psychiatry, 11 , Article 664. https://doi.org/10.3389/fpsyt.2020.00664

Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective Telemedicine Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective Abstract Small intestinal bacterial overgrowth (SIBO) remains one of the more frustrating conditions in gastroenterology—not because we can't treat it, but because it keeps coming back. Standard antibiotic therapy works, but relapse rates are discouragingly high. That's why many of us in integrative medicine and functional medicine have turned to low-dose naltrexone (LDN) as an adjunctive therapy. This article examines the science behind LDN, the clinical evidence supporting its use in SIBO, and what patients are actually experiencing. While we're still waiting on the randomized controlled trials we'd all like to see, the observational data, expert clinical experience, and patient-reported outcomes are compelling enough that LDN deserves serious consideration for patients with persistent SIBO. Keywords: Integrative Medicine, Functional Medicine, LDN, SIBO, low-dose naltrexone, small intestinal bacterial overgrowth, gut motility, immunomodulation, prokinetic therapy Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective Introduction If you've treated SIBO patients, you know the pattern: antibiotics work, symptoms improve, and then—often within weeks—everything returns. Small intestinal bacterial overgrowth affects patients with bloating, abdominal pain, diarrhea or constipation, and nutrient malabsorption (Pimentel et al., 2020). The condition can lead to poor absorption of fats, proteins, carbohydrates, and calcium, raising the risk of complications like osteoporosis. Certain populations face higher SIBO risk. Patients with chronic disease often experience more severe or recurrent symptoms. As we age, stomach acid decreases and motility slows—both risk factors. Previous abdominal surgery and structural abnormalities can impair the normal movement of waste from the small intestine into the large intestine, promoting bacterial buildup. Conventional management relies on antibiotics (typically rifaximin), low-FODMAP diets to limit carbohydrates that feed problematic bacteria, and prokinetic agents to restore motility. The problem? About two-thirds of successfully treated cases relapse within 2.5 months on average (Lauritano et al., 2008). That's why those of us practicing integrative medicine and functional medicine look beyond the standard playbook. We see SIBO as a symptom of deeper imbalances—impaired gut motility, immune dysregulation, intestinal barrier dysfunction, and dysbiosis. Low-dose naltrexone (LDN) addresses several of these underlying issues, which is why it's become an increasingly important tool in our practices. Understanding Low-Dose Naltrexone and Opioid Receptors Naltrexone has been around since 1984, FDA-approved as an opioid antagonist at 50 mg doses for treating alcohol and opioid addiction. Low-dose naltrexone is a different animal entirely. At doses of 0.5 to 4.5 mg—less than 10% of the standard dose—the drug does something unexpected (Younger et al., 2014). Here's how it works: LDN temporarily blocks opioid receptors for about four to six hours. The body responds by ramping up production of endogenous opioids—endorphins and enkephalins—natural peptides that modulate pain, immune function, and cell growth (Arata, 2018). After LDN clears, you're left with elevated endorphin levels for 18 to 20 hours. LDN also modulates toll-like receptor 4 (TLR4) pathways, producing anti-inflammatory and immune-regulating effects (Younger & Mackey, 2009). A few practical points: the typical research dose is 4.5 mg daily. Since no commercial low-dose formulation exists, patients obtain LDN from compounding pharmacies as capsules, sublingual drops, or creams. It's contraindicated with opioid medications. And unlike traditional opioid painkillers, LDN carries no addiction or dependence risk—making it a safer long-term option. Dr. Bernard Bihari pioneered LDN for autoimmune conditions back in 1985, and research has expanded its applications considerably since then. I should be clear: LDN use for SIBO is experimental. There are no formal guidelines or FDA approval for this indication. Our dosing and safety data come primarily from research studies and clinical experience rather than established protocols. That said, the safety profile is favorable, and the mechanistic rationale is sound. The Functional Medicine Approach to LDN in SIBO Those of us trained in functional medicine—whether through the Institute for Functional Medicine, the University of Arizona's integrative medicine fellowship, or similar programs—don't view SIBO as an isolated gut problem. It's a manifestation of interconnected imbalances: compromised motility, immune dysregulation, nutrient malabsorption, and disrupted gut-brain axis signaling. This perspective becomes especially valuable for complex or recurrent cases, particularly patients who also have autoimmune diseases, fibromyalgia, or other chronic inflammatory conditions. LDN fits naturally into this framework. By modulating opioid receptors in the central nervous system, it enhances endogenous opioid production and promotes natural anti-inflammatory effects. It helps regulate immune responses by reducing proinflammatory cytokines—supporting the body's own healing capacity rather than simply suppressing symptoms. In practice, I integrate LDN into comprehensive, individualized protocols. These typically include dietary interventions to reduce fermentable carbohydrates, targeted supplementation with fat-soluble vitamins and bile salts to optimize nutrient absorption, and prokinetic agents to address motility dysfunction. LDN often works alongside herbal antimicrobials and mind-body techniques like meditation. The goal is always to address root causes, not just manage symptoms. Patient education matters here. I spend time explaining why we're using LDN, what realistic expectations look like based on published outcomes, and how we'll adjust dosing based on individual response. This collaborative approach—where patients become active participants in their healing—tends to produce better long-term results for SIBO and related chronic conditions. Mechanisms of LDN Relevant to Small Intestinal Bacterial Overgrowth Several mechanisms make LDN relevant for SIBO. First, it has prokinetic properties—it enhances the migrating motor complex (MMC), the cyclical pattern of gut motility that sweeps bacteria and debris from the small intestine between meals (Siebecker, 2023). When the MMC doesn't function properly, bacteria accumulate. This is arguably the central problem in SIBO, and LDN helps address it. Second, LDN's immunomodulatory effects may tackle the autoimmune component of SIBO. Pimentel's research has shown that post-infectious SIBO involves autoantibodies against vinculin, a protein critical for intestinal nerve function (Pimentel et al., 2015). By modulating T-cell and B-cell activity through opioid growth factor (OGF) receptor interactions, LDN may reduce autoantibody production and help restore normal gut motility. LDN also acts on microglial cells in the central nervous system, decreasing neuroinflammation and downregulating proinflammatory cytokines. This mechanism may affect substance P, a neuropeptide involved in pain signaling—relevant for patients with concurrent fibromyalgia or chronic pain. In fact, LDN may be one of the first glial cell modulators used for chronic pain management. Third, LDN supports intestinal barrier integrity. The "leaky gut" associated with SIBO improves through TLR4-mediated anti-inflammatory effects, which promote mucosal healing and reduce bacterial translocation (Carnahan, 2016). Finally, by reducing the cytokine activation that perpetuates mast cell activation—a common comorbidity in complex SIBO cases—LDN addresses yet another piece of the puzzle. Clinical Evidence and Expert Perspectives Let me be honest about the evidence: we don't have large randomized controlled trials for LDN in SIBO specifically. What we do have is observational data, case series, and substantial expert clinical experience. Research has also explored LDN's benefits in Crohn's disease, multiple sclerosis, rheumatoid arthritis, and as a cancer treatment adjunct. Ploesser et al. (2010) surveyed LDN use in gastrointestinal disorders and found that among patients with IBS and evidence of SIBO, 17.6% reported marked improvement and 37.6% reported moderate benefit. Overall, about 68% showed symptomatic improvement. Patients commonly report better sleep quality, reduced fatigue, improved mood, and increased mobility as pain and inflammation decrease. Dr. Leonard Weinstock, a gastroenterologist at Washington University and medical advisor for the LDN Research Trust, has published extensively on LDN in GI conditions. His 2018 BMJ Case Reports paper documented successful treatment of POTS and mast cell activation syndrome using combined LDN, immunoglobulin, and antibiotics for concurrent SIBO (Weinstock et al., 2018). He's stated publicly that LDN is indispensable in his practice, having prescribed it to thousands of patients. Dr. Allison Siebecker, who specializes in SIBO, includes LDN among her recommended prokinetic options for relapse prevention. It's not technically a prokinetic, but it has prokinetic effects plus additional benefits: immune balancing, inflammation reduction, mood improvement (Siebecker, 2023). Dr. Michael Ruscio uses LDN in his SIBO protocols, particularly for patients with extra-intestinal manifestations like restless leg syndrome, rosacea, and chronic fatigue. When the big names in this field are all using it, that tells you something. Patient Community Perspectives Patient testimonials add real-world context to the clinical data. Many patients with chronic disease or autoimmune conditions seek out LDN hoping to address multiple health concerns simultaneously. The LDN Research Trust has documented numerous patient stories where individuals report expanded dietary tolerance, reduced joint pain, and return to normal activities after years of SIBO-related restrictions (LDN Research Trust, 2023). One patient described finally being able to "expand her diet and return to regular exercise, removing the joint pain" that had plagued her. In Weinstock's 2018 case report, a patient with severe POTS, MCAS, and SIBO wrote: "I feel like I won the lottery last year by discovering LDN, IVIg and SIBO treatment. LDN made me feel noticeably happier, more energetic, in less pain and with better digestion." Online forums like Health Rising and the Low Toxin Forum feature ongoing discussions about LDN for SIBO. Users share experiences of improved motility, reduced bloating, and better energy. A common theme: LDN requires gradual titration, and some patients do best at doses below the standard 4.5 mg target. These reports align with what I see clinically. Individualized dosing matters. Combination protocols—LDN plus dietary interventions, antimicrobials, and other prokinetics—tend to work better than any single intervention alone. Clinical Application of LDN in SIBO In my practice, I typically start LDN at 0.5 to 1.5 mg at bedtime, titrating gradually over two to four weeks toward 4.5 mg based on tolerance (Weinstock, 2018). Some patients do better at lower maintenance doses—another reason individualized care matters. I often combine LDN with conventional prokinetics like low-dose erythromycin or prucalopride, herbal prokinetics such as ginger and Iberogast, rifaximin or herbal antimicrobials for bacterial reduction, and dietary interventions including low-FODMAP or elemental diets. Side effects are generally mild: vivid dreams, insomnia, headaches, and occasionally GI upset. About 10-15% of patients experience insomnia, which often resolves with morning dosing instead. The absolute contraindication is concurrent opioid use—LDN will precipitate withdrawal. The key point I emphasize with patients: LDN is one component of comprehensive SIBO management, not a standalone cure. We're always addressing underlying causes—motility dysfunction, dietary triggers, immune dysregulation. Conclusion Low-dose naltrexone offers something we don't often see: a single intervention that addresses multiple SIBO-related mechanisms. Prokinetic effects, immunomodulation, anti-inflammatory activity, intestinal barrier support—it's a multitasker with a favorable safety profile. The evidence base isn't where we'd like it to be; we need randomized controlled trials specifically examining LDN for SIBO eradication and relapse prevention. Until that research arrives, LDN remains a reasonable consideration for treatment-resistant SIBO, especially in patients with comorbid conditions like mast cell activation syndrome, POTS, or autoimmune features. We should counsel patients about off-label use while acknowledging what clinical experience consistently shows: for many patients, LDN makes a meaningful difference. In integrative medicine and functional medicine, that's often enough to warrant a thoughtful trial. Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective About Dr. Kim's Telemedicine Practice At www.directintegrativecare.com , Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician www.directintegrativecare.com Meet Dr. Kim - Yoon Hang Kim MD MPH Integrative Medicine, Functional Medicine, Metabolic Medicine Expert and LDN Authority References Arata, M. (2018). Low dose naltrexone (LDN) and small intestinal bacterial overgrowth (SIBO)  [Conference presentation]. LDN Research Trust Conference. Carnahan, J. C. (2016). Low dose naltrexone (LDN): The treatment you've never heard of. International Journal of Complementary & Alternative Medicine, 4 (3), 00123. https://doi.org/10.15406/ijcam.2016.04.00123 Lauritano, E. C., Gabrielli, M., Scarpellini, E., Lupascu, A., Novi, M., Sottili, S., ... & Gasbarrini, A. (2008). Small intestinal bacterial overgrowth recurrence after antibiotic therapy. American Journal of Gastroenterology, 103 (8), 2031-2035. LDN Research Trust. (2023). Patient testimonials and resources.   https://ldnresearchtrust.org Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. American Journal of Gastroenterology, 115 (2), 165-178. https://doi.org/10.14309/ajg.0000000000000501 Pimentel, M., Morales, W., Pokkunuri, V., Brikos, C., Kim, S. M., Kim, S. E., ... & Chang, C. (2015). Autoimmunity links vinculin to the pathophysiology of chronic functional bowel changes following Campylobacter jejuni  infection in a rat model. Digestive Diseases and Sciences, 60 (5), 1195-1205. Ploesser, J., Weinstock, L. B., & Thomas, E. (2010). Low dose naltrexone: Effects on medication in chronic pain and fatigue syndromes. International Journal of Pharmaceutical Compounding, 14 (5), 360-364. Siebecker, A. (2023). Prevention of SIBO relapse.  SIBO Info. https://www.siboinfo.com/prevention-of-relapse.html Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, 2018 , bcr-2017-221405. https://doi.org/10.1136/bcr-2017-221405 Younger, J., & Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine, 10 (4), 663-672. Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451-459. https://doi.org/10.1007/s10067-014-2517-2 Disclaimer This article provides an evidence-informed overview of low-dose naltrexone for SIBO within integrative and functional medicine frameworks. The information presented is for educational purposes only and does not constitute medical advice. Readers should consult qualified healthcare professionals for personalized treatment decisions. LDN use for SIBO is considered off-label and should be prescribed and monitored by appropriately trained clinicians.